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Abstract 
Tuberculosis, bacterial community-acquired pneumonia (CAP), and Pneumocystis jirovecii 
pneumonia (PJP) are the commonest causes of hospitalisation in HIV-infected individuals. 
Prompt diagnosis and treatment initiation are important to reduce morbidity and mortality, but 
are hampered by overlap in clinical and radiological presentation and limited diagnostic 
resources in resource-poor settings. Simple, affordable tests are needed for developing 
improved clinical algorithms. C-reactive protein (CRP) and procalcitonin have shown 
diagnostic utility for respiratory tract infections, however few studies have focussed on their 
ability to distinguish between tuberculosis, CAP, and PJP in adult HIV-infected inpatients.  
We performed a cross-sectional study on secondary data to evaluate the diagnostic accuracy 
of C-reactive protein (CRP) and procalcitonin compared to composite reference standards, to 
discriminate between the three target infections in HIV-infected inpatients. Participants had 
been recruited in two district level hospitals in Cape Town, South Africa, admitted with 
current cough and danger signs in accordance with the WHO algorithm for tuberculosis in 
seriously ill HIV-infected patients. Study clinicians were blinded to CRP and procalcitonin 
results and laboratory staff who performed biomarker tests on stored serum were blinded to 
patient diagnoses. 
248 participants met study criteria and case definitions: 133 with tuberculosis, 61 with CAP, 
16 with PJP, and 38 with mixed infection. Elevated CRP was found in 98% of participants. 
The cutoff used to guide antibiotic initiation in lower respiratory tract infections correctly 
identified 82% of those with CAP, 84% with tuberculosis and 50% with PJP. The differences 
in median CRP and procalcitonin concentrations between the three infections were 
statistically significant, but distributions overlapped considerably, and CRP and procalcitonin 
cut-offs with sensitivities of ≥ 90% were found for all three target infection pairs, however 
corresponding specificities were low. Receiver operating characteristic areas under the curve 
for CRP and procalcitonin were between 0.68 and 0.74 for PJP versus tuberculosis and PJP 
versus CAP.  
CRP and procalcitonin showed limited value in discriminating between the three target 
infections due to widely overlapping distributions, but diagnostic accuracy was higher for 
discriminating PJP from CAP or tuberculosis. Our findings suggest that CRP and 
procalcitonin may have greater diagnostic utility as part of a panel of biomarkers or in clinical 
prediction rules.  
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1. Summary
HIV-related tuberculosis (TB), bacterial community-acquired pneumonia (CAP) and pneumocystis 
jirovecii pneumonia (PJP) are major causes of hospitalisation, particularly in low and middle income 
countries with high HIV disease burden. Lack of optimal diagnostic algorithms adds to the challenge 
of differentiating between the three infections and delays initiation of appropriate treatment. This 
study seeks to explore the diagnostic accuracy of  two non-specific inflammatory biomarkers: C-
reactive protein and procalcitonin that have shown some promise for discrimination between HIV-
related respiratory infections of different aetiologies. To date, their performance is incompletely 
defined and further studies are needed to evaluate their potential as part of diagnostic algorithms.  
2. Background
Respiratory infections in HIV-infected people are a major cause of hospitalisation (1), and mortality 
and morbidity are negatively influenced by delayed treatment or initiation of inappropriate therapy as 
a result of diagnostic delay (2). 
Defining the aetiology of respiratory infection in HIV patients remains a significant challenge as there 
is considerable overlap in the clinical and radiographic presentation of the three commonest 
respiratory infections: pulmonary tuberculosis, bacterial community-acquired pneumonia, and 
Pneumocystis jirovecii pneumonia. Utility of current diagnostic methods is hampered by resource 
constraints in low and middle income countries, and poor performance of available laboratory 
diagnostic methods (3-5). There is an on-going search for effective and affordable alternative 
diagnostic measures to improve patient outcomes. 
Patient management is guided by a widely used clinical screening algorithm: the World Health 
Organization algorithm for the diagnosis of tuberculosis in seriously ill patients presenting with 
severe symptoms of respiratory infection  The recently 2016 updated version (6) introduced some 
improvements to the previous 2007 algorithm, however there remains an absence of effective triage 
Student: Fiona Mendelson (MNDFIO001), Aug 2016	
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tests to assist clinicians in determining who needs further more complex diagnostics recommended by 
the algorithm, such as Xpert MTB/RIF, or who requires empiric PJP treatment.  
Improved diagnostic algorithms employing assays suitable for low-resource settings would help to 
prevent delay to diagnosis and initiation of treatment, and avoid inappropriate treatment or 
unnecessary.  C-reactive protein and procalcitonin are two non-specific inflammatory biomarkers that 
have been identified as having potential value as triage tests in algorithms for patients with respiratory 
illnesses. A number of studies have explored diagnostic value of C-reactive protein for ruling out 
tuberculosis, particularly in HIV-infected patients with smear-negative disease (7,8), whilst to date, 
the main utility of PCT testing for respiratory infections in non-HIV infected populations has been to 
rule-out bacterial infection and to aid appropriate antibiotic prescribing (9).   
We conducted a systematic literature search for studies involving HIV-infected individuals with two 
or more of the target diseases and C-reactive protein and/or procalcitonin testing. This search yielded 
few studies and fewer still that reported diagnostic accuracy measures. Only two studies reported 
diagnostic accuracy for C-reactive protein in all three infections, with conflicting results. One case 
notes review found poor specificity in discriminating between the three (10), whereas the other found 
higher specificity (82%) in discriminating CAP from the other respiratory infections, however CRP 
was combined with another  biomarker and participant selection included hospital acquired 
respiratory infections and other mycobacterial infections beside tuberculosis (11). A South African 
study (12) found good sensitivity for both biomarkers in discriminating CAP from tuberculosis, 
although selection was for participants with suspected CAP and may mean that tuberculosis was 
underrepresented in analyses. We only identified one study for procalcitonin that found statistically 
significant differences in concentrations between each of the three infections, however no diagnostic 
accuracy analyses were reported (13).  
Student: Fiona Mendelson (MNDFIO001), Aug 2016	
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3. Rationale
This study is designed to explore the diagnostic accuracy of C-reactive protein and procacitonin in 
seriously ill adult HIV-infected inpatients with suspected respiratory infection, towards determining 
whether either have potential utility as a triage test in a diagnostic algorithm. This study is related to a 
larger main study aimed at improving current algorithms for managing tuberculosis.  
For this purpose, we propose a secondary analysis of the main dataset: a large prospective HIV-
infected cohort, recruited from two secondary level hospitals in Cape Town South Africa, serving 
high HIV and TB prevalence communities.  
4. Research Question and Objectives
4.1 Research Question: 
What is the diagnostic accuracy of C-reactive protein and procalcitonin, compared with composite 
reference standards, to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia and 
bacterial community-acquired pneumonia in adult HIV-infected inpatients meeting criteria for 
seriously ill?  
4.2 Primary objective: 
To determine diagnostic accuracy of C-reactive protein and procalcitonin in predicting presence or 
absence of each of the three target infections. 
4.3 Secondary objectives: 






i. To determine optimal concentration cutoffs for C-reactive protein and procalcitonin for 
discriminating between those with and without each of the three target infections 
ii. To determine to what extent C-reactive protein and procalcitonin concentrations differ 
between each target infection 
 
5. Methods  
 
5.1 Study design 
This is a cross sectional diagnostic accuracy study, using secondary analysis of prospective cohort 
data. Our objectives are closely linked to those of the main study, which was designed to determine an 
evidence base for the development of improved algorithms in the management of seriously ill HIV-
infected patients with tuberculosis (14). This study will comply with STARD guidelines (15). 
 
5.2 Population and sampling  
 
5.2.1 Population  
Recruitment for the main study took place at two secondary level hospitals in Cape Town South 
Africa, serving over-lapping high HIV and tuberculosis prevalence communities. 195 patients were 
recruited from GF Jooste District Hospital from November 2011 to March 2013 and, following the 
closure of that hospital, 289 patients from Khayalitsha District Hospital from March 2013 to October 
2014. 
 
5.2.2 Method of sampling for the main study 
Consecutive enrolment took place daily over the study period. Inclusion criteria were as follows: adult 
patients (aged 18 years and over), admitted to either study site, with cough of any duration and one or 
more danger signs defined in the WHO screening algorithm: respiratory rate >30/min, fever > 39o C, 
pulse rate > 120/min and unable to walk unaided.  All new medical admissions were screened for 






study eligibility by the study research worker and study doctor. 
Inclusion criteria were: 
• Aged 18 and over   
• HIV-infected (documented or confirmed on admission) 
• Current cough of any duration with one or more WHO danger signs 
• Sputum sample obtained  
Exclusion criteria were: 
• Failure to meet inclusion criteria 
• Failure to consent  
• History of tuberculosis and use of anti-tuberculosis therapy: either current use, completed 
within the previous month or defaulted treatment in the past 6 months 
• Exacerbation of congestive congestive cardiac failure or chronic obstructive pulmonary 
disease  
• Failure to provide a spontaneous or induced sputum specimen using an ultrasonic nebulizer 
and hypertonic saline 
 
5.2.3 Participant selection for this study 
Our study involves a sub-set of 388 of the original 500 participants patients enrolled from March 2012 
to October 2014: 69 patients from GF Jooste District Hospital and 261 patients from Khayalitsha 
District Hospital. Funding for biomarker assays only became available after the start of the main study 
therefore participants enrolled prior to March 2012 were excluded. Our assumption is that the only 
difference between the main and sub-sets is enrollment date and does not pose a risk of bias.  
Of the 388 patients, 248 met case definitions for one or more of the three target diseases and 10 
patients had other definitive diagnoses, (case definitions are described in full in Section 6.3) . We 
excluded 58 patients who could not be categorised due to missing radiological data and 72 patients 
who did not meet case definitions.  
 







Diagnoses of excluded patients 
Of the remaining 82 patients, 10 had confirmed diagnoses other than tuberculosis, CAP or PJP and  
72 were empirically diagnosed with one or more of the three target diseases but did not meet case 
definitions. Analysis of these 72 as ‘probable cases’ was rejected due to high prevalence of dual 
infection.  
10 patients with confirmed diagnoses other than the target diseases were as follows: 
• 2 patients with laboratory confirmed meningitis (1 with non-tuberculous mycobacterium)  
• 1 patient had laboratory confirmed disseminated Cryptococcus  
• 1 patient had laboratory confirmed emmonsia 
• 1 patient had laboratory confirmed disseminated Cryptococcus and emmonsia  
• 4 patients had bronchitis 
• 1 patient had post-TB bronchiectasis with a pneumothorax 
 
72 patients who did not fulfill case definitions were as follows: 
• 26 patients with an empirical diagnosis of tuberculosis (and negative cultures) who were 
commenced on anti-tubercular treatment. 20 of these had coinfection with another pathogen.  
• 59 patients with an empirical diagnosis of CAP (15 coinfected with TB) 
• 4 patients with empirical diagnosis of PJP, (2 coinfected with TB) 
 
Diagnoses of participants meeting case definitions 
248 patients met one or more of the three target disease case definitions: 164 patients with 
tuberculosis, 98 with CAP, 24 with PJP; and 38 with mixed infection: 30 were coinfected with 
tuberculosis and CAP, 1 with tuberculosis and PJP, and 7 with CAP and PJP. Participants with more 
than one of the three target infections will be excluded from primary analysis as it is impossible to 
determine the contribution of each disease to the index test results. However, this unavoidably reduces 
our sample size. 







5.2.4. Power calculation 
Software used: STATA version 13.0 (StataCorp Inc. College Station, Texas, USA).  
Power calculation for objective 1: 
Using our fixed sample size consisting of single case-defined infections, we explored precision to 
detect 90% sensitivity for each biomarker for each of the three target infections versus the other 
two, with a proposed aim of ± 10% variation in 95% confidence intervals. Since we are 
evaluating performance of C-reactive protein and procalcitonin as triage tests, we selected 
sensitivities rather than other measures and minimum 90% was selected from WHO 
recommendations (16) . Our power calculation was limited by the availability of relevant studies 
reporting diagnostic measures. Our criteria for selection was any study reporting sensitivity for 
either biomarker in discriminating any of the three target infections in HIV-infected adults (8, 12, 
17).  
Expected sensitivities for each target infection were restricted to C-reactive protein as among studies 
evaluating procalcitonin in HIV-infected individuals with respiratory infections, none reported 
diagnostic measures. We explored a range of sensitivites with confidence interval of binomial 
proportions of 95% and 99%, using the Wilson-score interval, which is suited to smaller sample sizes 
(18). Since our data was not normally distributed, a second calculation was made using 85% of the 
original sample sizes as suggested by Lehmann (19). We estimated 95% CIs of 90% sensitivity to be 
83%-94% for tuberculosis, 79%-96% for CAP, and 69%-99% for PJP. The small sample size for PJP 
accounted for wide 95% confidence intervals. 
 
Power calculation for objective 2: 
We explored power to detect mean differences between PCT and the three target diseases and 
between CRP and the three target diseases by estimating power for a two-sample means test, 
assuming unequal variances. We considered significance levels of 0.05 and 0.10 and 100% and 






85% sample sizes. Estimations for procalcitonin were based on one study (13) with HIV-infected 
individuals with suspected CAP that reported mean effect sizes (with wide 95% CIs). 
For C-reactive protein, we were only able to base calculations on studies reporting means and 
standard deviations for CRP in non-HIV infected individuals with tuberculosis or CAP (20-22). 
Taking 80% as an accepted minimal power and alpha 0.05 and 85% sample size as our most 
conservative estimate, our study is adequately powered to detect minimum procalcitonin mean 
concentration differences of 50% between tuberculosis and PJP, 62% between CAP and PJP, 62% 
between CAP and tuberculosis and minimum C-reactive protein mean concentration differences of 





6.1 Types of measurements 
• Laboratory and microbiological analyses 
o Three sputum samples on admission were sent for Gram stain, culture, and 
sensitivity, auramine staining for acid-fast bacilli (AFB), liquid mycobacterial culture 
and Xpert MTB/RIF  
o Blood samples on admission were sent for mycobacterial culture, full blood count, 
CD4 count and haemoglobin concentrations 
o Stored serum was used for C-reactive protein and procalcitonin assays, and β-D-
glucan 
o Extra pulmonary samples (for example pleural fluid) were sent for mycobacterial 
culture 
• Radiological: Chest x-rays were performed on admission and reviewed by a specialist 
radiologist, who was blinded to diagnoses and laboratory investigation results. An 






experienced ultrasonographer performed an abdominal ultrasound within three days of 
admission to detect extra pulmonary or disseminated tuberculosis.   
 
• Clinical: On admission, the study doctor carried out complete patient history and physical 
examination and oxygen saturation measurements.  
 
6.1 Biomarker assays 
A sample of blood was obtained from each participant on admission. Once clotted, samples were 
centrifuged and spun at 3500rpm for 10 minutes. The separated serum was decanted into sterile 
tubes, labelled with the patient’s initials and study number and stored in a refrigerator at minus 70°C.  
For the purpose of this study stored serum from participants was analysed retrospectively. C-reactive 
protein and procalcitonin results had no role in patient referral or management and laboratory staff 
were blinded to patient diagnosis and outcome. Laboratory–based assays were performed at the 
National Health Laboratory Service (NHLS), Charlotte Maxeke Johannesburg Academic Hospital 
and the following assays were used: 
• C-reactive protein using Siemens Advia 1800. Normal range <10mg/L and assay range 4-
[304-336] mg/L 
• Procalcitonin (sensitive) using Siemens Advia Centaur XP. Normal range for adults  
<0.02µg/L and assay range 0.02-75µg/L  
 
6.2 Reference standards 
Case definitions for each diagnosis were as follows: 
Tuberculosis 
a. postitive Mycobacterium tuberculosis culture from any site; AND 
b. at least one symptom consistent with tuberculosis (cough, fever, night sweats, weight loss) 
Community-acquired bacterial pneumonia, taken from Scott et al. (23). 






a. cough ≤ 14 days; AND 
b. one or more additional respiratory symptoms: sputum, breathlessness, chest pain, 
haemoptysis, or fever; AND 
c. radiological evidence of pulmonary consolidation (confirmed by a radiologist) 
Pneumocystis jirovecii pneumonia, adapted from Centre for Disease Control (24). Full reference 
case definition and rationale for modifications are provided in table 1. 
a. cough ≤ three months (84 days); AND 
b. radiological evidence of diffuse bilateral interstitial infiltrates (confirmed by a radiologist); 
AND 
c. oxygen saturation ≤ 92%  
Table 1: CDC reference case definition for PJP and rational for modifications 
 CDC case definition in the absence of 
laboratory confirmation 
Case definition for this 
study 





















History of dyspnoea on exertion or 
nonproductive cough of recent onset 
(within the past 3 months); AND 
 
Chest x-ray evidence of diffuse 
bilateral interstitial infiltrates or 
gallium scan evidence of diffuse 




Arterial blood gas analysis showing an 
arterial pO2 of <70mmHg or a low 
respiratory diffusing capacity (<80% of 
predicted values) or an increase in the 
alveolar-arterial oxygen tension 
gradient; AND  
 
 
No evidence of a bacterial pneumonia 
 
Cough ≤ three months 
(84 days); AND 
 
 
Radiological evidence of 
diffuse bilateral 
interstitial infiltrates 




Oxygen saturation ≤ 92%  
 
Participants were recruited for 
main study with cough of any 
duration 
 
Expert radiological opinion 
was applied to all study 





Pulse oximetry was 
performed on all patients on 
admission. Senior study 
clinicians determined 92% as 
a conservative proxy for pO2 
70mmHg (25) 
 
Only patients who are not co-
infected (ie only meet one of 
the three study case 
definitions are included in 
primary analysis 
 







7. Analysis Plan 
 
7.1.Statistical software 
STATA version 13.0 (StataCorp Inc, College Station, Texas, USA) will be used for analysis.  
7.2.Baseline variables 
The cohort will be described using the variables in table 2. For biomarker analyses, C-reactive protein 
and procalcitonin values below the detectable limit (BDL) of the assay will be substituted with half 
BDL (in preference to substitution with the assay limit or with zero, both of which have been shown 
to bias parameter estimates (26) . Summary statistics will be provided for overall measurements and 
























Table 2: Baseline variables  
 
 
7.3. Outcome measures 
Participants with more than one of the three target infections will be excluded from diagnostic 
analysis as it is impossible to determine the contribution of each disease to biomarker concentrations. 
Variable Type of variable Measurement 
Independent variables 
Age Continuous Mean & SD or median & IQR  
Gender Categorical binary  0/1 Male/Female 
Diagnosis Categorical: binary or  
nominal depending on 
analysis 
Case-defined tuberculosis, CAP, PJP, co-
infections, other infections & non-case-
defined empirical diagnoses   
CD4 count Continuous  Mean & SD or median & IQR 
White cell count Continuous Mean & SD or median & IQR 
Haemoglobin concentration Continuous Mean & SD or median & IQR 
β-D-glucan Continuous Mean & SD or median & IQR 
Antiretroviral therapy 
(ART) status 
Categorical binary 0/1 Currently not taking ART/taking ART 
Antibiotic prophylaxis on 
admission 
Categorical binary 0/1 Not taking prophylaxis/taking 
prophylaxis 
Antibiotic therapy 
commenced prior to index 
test measurements 
Categorical binary 0/1 Not commenced/commenced 
Cotrimoxazole prophylaxis 
prior to admission 
Categorical binary 0/1  Not taking prophylaxis/taking 
prophylaxis 
Heart rate>120 b/m Categorical binary 0/1 Over 120 or ≤ 120 
Respiratory rate >30/min Categorical binary 0/1 Over 30 or ≤ 30 
Temperature > 39oC Categorical binary 0/1 Over 39 or ≤ 39 
Inabilty to walk unaided Categorical binary 0/1 walked in unaided or not 
Dependent variables 
C-reactive protein Numerical Median & IQR 
Procalcitonin Numerical Median & IQR 






However, this unavoidably reduces our sample size, which is too small for generating a training set. 
However, appropriate cross-validation methods will be applied to the data.  
 
Outcome measure 1:  
Logistic regression will be used to generate receiver operating characteristic curves (ROC) and area 
under the curve (AUC) estimates for C-reactive protein and procalcitonin for each target infection 
versus the other two and for each target infection pair.  
 
Outcome measure 2: 
ROC analysis will be used to estimate sensitivity, specificity, positive predictive value, negative 
predictive value, likelihood ratios and diagnostic odds ratios and AUCs (with 95% confidence 
intervals) for selected cutoffs for C-reactive protein and procalcitonin for each target infection versus 
the other two and for each target pair. 
 
Outcome measure 3:  
Our biomarker data is not normally distributed, therefore we will estimate median concentrations plus 
inter-quartile range (IQR) for C-reactive protein and procalcitonin for target infection. Differences in 
biomarker medians between the three infections will be analysed using the Kruskal-Wallis test, and 
between infection pairs using the Wilcoxon-Mann-Whitney test. 
 
8. Ethics 
The University of Cape Town Human Research Ethics Committee granted ethical approval for the 
main study HREC REF: 334/2011, renewal date 30/05/2016 (Appendix I). 
 
8.1. Informed Consent 






Participant consent was obtained by the study research worker, in English or Xhosa according to 
participant preference, filed with the source documents and checked for completion by the study 
doctor. Consent was deferred in any participants admitted in a confused state until an orientated 
condition was restored. Participants were able to withdraw from the study at any time.  
 
8.2 Confidentiality 
On enrolment, participants were de-identified and coded using a study number and own initials. 
All clinical information and investigation results were recorded on case report forms, stored in a 
dedicated folder in an on-site locked filing cabinet. Any corrections to the documents were signed 
and dated. Data was entered no less than weekly onto the password-protected database and 
backed up. Chest x-rays were digitally recorded, de-identified and stored on the study computer. 
Source documents will be stored by the principal investigator for a minimum of five years after 
the completion of the study and digital x-ray images retained. 
 
8.3. Patient benefits and harms 
This analysis poses no risk or discomfort to participants, as it will not involve further human 
subjects research. Blood serum used for biomarker assays was obtained from blood samples taken 
as part of routine care; all tests performed were part of standard diagnostic investigations, or for 
study as potential improvements to treatment algorithms. C-reactive protein and procalcitonin 
were done on stored serum in a batch after the study, therefore these tests had no role in patient 
management. Comparison reference standards comprised investigations that were also part of 
standard care.  
 
All participants received routine standard of care, including appropriate investigations, clinical 






review and initiation of antimicrobial therapies as per national guidelines. The admitting medical 
team was responsible for overall care and patient management.   
For those whose HIV status was unknown or unconfirmed, HIV testing was performed as per 
national protocol. On discharge, access to antiretroviral therapy via local community clinics, 
appropriate to the individual patient, was organized.  
Post-discharge clinical review was arranged on day 28 and 56 from enrolment to assess clinical 
response and outcome; this was brought forward if clinically indicated. Participants were 
reimbursed with R150 for attending the 28-day clinic follow-up appointment. The admitting 
medical team arranged readmission or further follow-up as necessary. Participants attending 
community TB/HIV clinics were provided with their final tuberculosis culture results to take to 
their clinics. 
 
9. Stakeholders/dissemination of results 
Stakeholders are patients at risk of the three target diseases, particularly in resource constrained 
settings with high HIV and TB prevalence and the clinicians and policy-makers involved in their 
care. Plans to distribute findings include publication and conferences.  
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HIV- related respiratory infections are a major cause of hospitalisation globally, particularly in low 
and middle-income countries (LMICs) with high HIV disease burden. (1)  
Defining the aetiology of respiratory infection in HIV patients remains a significant challenge as there 
is considerable overlap in the clinical and radiographic presentation of the three commonest 
respiratory infections: pulmonary tuberculosis, bacterial community-acquired pneumonia (CAP), and 
Pneumocystis jirovecii pneumonia (PJP). Mortality and morbidity in HIV-related pulmonary 
infections is negatively influenced by delayed treatment or initiation of inappropriate therapy as a 
result of diagnostic delay (2); poorly performing diagnostic methods, resource constraints and long 
waiting times for results hamper utility of current management algorithms. There is an on-going 
search for effective and affordable alternative diagnostic measures to facilitate appropriate treatment. 
The focus of our study is to evaluate the possible potential of two biomarkers as triage tests for adult 
HIV-infected inpatients presenting with symptoms of respiratory infection of unknown aetiology.  
 
 
 2. Burden of disease 
Tuberculosis is a major global health burden. In 2015, the World Health Organization (WHO) 
estimated 10.4 million new cases and 1.8 million deaths, approximately a fifth being in HIV-infected 
individuals  (3). Overall fatality rates showed wide geographical variation with the highest in the 
WHO African Region, which the report attributed to sub-optimal diagnostic tools and treatment 
services. (3). A systematic review of causes of hospital admission among people living with HIV 
worldwide found that tuberculosis accounted for 18%, and 27% of deaths (1). 
 
In the same study, bacterial pneumonia accounted for 15% of hospital admissions and 17% of deaths. 
(1) CAP may occur at any stage of HIV infection, but more commonly at CD4 counts less than 200 
cells/µl. (2). Causative organisms are the same as in the non-HIV infected population and include 
common Gram-positive bacteria, aerobic Gram-negative bacilli and atypical pathogens. (2). A global 
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review of CAP (4) found comparable incidence of atypical organisms across all regions of 20-28%. 
Although Asia and Africa were not as well represented as other regions, the review reported low 
antibiotic coverage for atypical pathogens in Asian and African settings, resulting in longer hospital 
stays and higher mortality.  
 
PJP caused by the fungus Pneumocystis jirovecii is a major opportunistic infection in HIV-infected 
persons; prevalence varies, due in part to geographical differences in prophylaxis use and 
effectiveness (5). In the Ford et al. systematic review, PJP was responsible for 8% of admissions and 
13% of deaths (1).  
 
3. Diagnosis of HIV-related pulmonary infection 
 
3.1 Current diagnostic methods 
Differentiation between tuberculosis, CAP and PJP is not straightforward.  In HIV-infected persons, 
atypical and ambiguous radiological presentation and overlapping clinical features pose an additional 
challenge to distinguishing between these three infections (6, 7). Furthermore, patients with 
tuberculosis and HIV have higher rates of smear-negative and extra pulmonary disease, compounding 
diagnostic difficulties by reducing performance of commonly used diagnostic measures for detecting 
tuberculosis (8, 9).  
Aetiological diagnosis generally relies on laboratory methods to identify the causative organism, 
however each type of diagnostic test has disadvantages. In LMICs, diagnosis of PJP generally rests on 
radiological and clinical findings (10). Microscopy for Pneumocystis pneumonia requires induced 
sputum or bronchoalveolar lavage, obtained by invasive procedures; it is also expensive and seldom 
used in resource-constrained settings, whilst expectorated sputum has prohibitively poor sensitivity 
(10).   
Sputum culture for CAP is subject to contamination by upper respiratory flora and both sputum and 
blood culture have been shown to have poor sensitivity and limited use in guiding patient 
management (11-13). Mycobacterium tuberculosis culture is not always available in low-resourced 
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settings and can take several weeks to process, contributing to delayed diagnosis (14); liquid media 
culture is faster than solid but prone to contamination (15). In addition, culture-based diagnostics are 
costly and challenging for resource-limited settings with poor laboratory infrastructure (16). 
Sputum smear microscopy remains the most commonly available diagnostic test in resource-limited 
settings and has a high specificity but low sensitivity due to reduced bacillary load associated with 
HIV infection (17). Polymerase chain reaction (PCR)-based Xpert MTB/RIF is more sensitive than 
smear microscopy, although sputum-smear negative tuberculosis is associated with reduced 
sensitivity (14, 18), and although there have been substantial advances in scaling up, not all low 
income countries with high tuberculosis disease burden have the infrastructure to support high-level 
coverage (19).  
 
3.2 WHO clinical screening tool for HIV-related pulmonary infection  
To improve diagnosis of tuberculosis in high HIV prevalence settings, WHO introduced 
recommendations to guide initiation of empiric tuberculosis treatment, including a clinical screening 
algorithm for seriously ill patients presenting with cough of >2 weeks duration plus any of the 
following danger signs: respiratory rate >30 /min, fever >39oC, pulse rate >120 /min or unable to 
walk unaided (20) (Appendix 1).  
In response to the highlighting of weaknesses in the algorithm, WHO introduced a revised version in 
2016 that included improvements such as defining the target patient as presenting with current cough 
instead of cough > 2 weeks (21) (Appendix 2). There are still obvious gaps. The algorithm 
recommends initiation of broad-spectrum antibiotics, and that treatment for PJP should be considered 
(without giving guidance on selection of patients for empiric PJP therapy).  Diagnosis of tuberculosis 
is based on a rapid nucleic acid amplification test (the Xpert MTB/RIF assay), and empiric therapy for 
tuberculosis is recommended if the Xpert MTB/RIF assay is negative or unavailable and there is no 
response to antibiotics.  
In the absence of optimal diagnostic facilities and tools, prescriber reliance on stepwise empiric 
treatment can delay commencing correct treatment, which adversely impacts morbidity and mortality 
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(22). On the other hand, inappropriate use of antimicrobials for patients whose diagnosis is 
unconfirmed poses risk of toxicity for the patient, incurs unnecessary costs, wastes valuable resources 
and results in increased resistance, threatening therapeutic and prophylactic antimicrobials (2, 10, 23). 
There is a pressing need for alternative diagnostic tests, suited to the triage of patients in high HIV 
burden, resource-constrained settings.  
Procalcitonin (PCT) and C-reactive protein (CRP) are two non-specific inflammatory biomarkers that 
have been proposed as possible adjunct tests to diagnostic algorithms and treatment guidelines, to 
improve triage of patients and optimise the use of resources.  
 
 
4. C-reactive protein and procalcitonin testing  
4.1 C-reactive protein testing in non-HIV infected populations  
C-reactive protein is a non-specific acute phase protein released by the liver in response to 
inflammatory cytokines (24) and used as a non-specific marker of inflammation. Typically, 
significantly higher serum concentrations are found in bacterial compared to viral infection and C-
reactive protein testing has an established role in differentiating between the two (25). In a Korean 
study of non HIV-infected individuals in an intermediate tuberculosis burden setting, C-reactive 
protein has shown utility for distinguishing between CAP and tuberculosis (26).  
4.2 CRP testing in HIV-infected patients 
The findings of a 1993 Danish study suggested that CRP response is poorer in those with advanced 
HIV infection (27); however, a more recent study showed no correlation between C-reactive protein 
concentration and HIV status, degree of immunodeficiency or antiretroviral therapy (28). Elevated 
concentrations have been found in patients with CAP (7, 29, 30), whereas low to modest 
concentrations have been reported in patients with PJP (29-31). Active Mycobacterium tuberculosis 
infection in HIV-infected patients is associated with mild or moderate elevations in C-reactive protein 
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concentrations (7, 28, 30, 32, 33), and positive correlation between C-reactive protein concentrations 
and increased mycobacterial load, as well as increased concentrations in extra-pulmonary tuberculosis 
compared to pulmonary tuberculosis have been reported (17, 33). 
Several South African studies have focused on the diagnostic value of C-reactive protein in ruling out 
TB in HIV-infected patients with smear negative disease (14, 33). Alvarez and colleagues 
demonstrated that C-reactive protein testing significantly improved the performance of a prediction 
model in diagnosing smear-negative tuberculosis in HIV-infected and -uninfected patients with 
suspected tuberculosis. Patients suspected as having tuberculosis with a normal C-reactive protein 
result were reclassified as low risk and allocated a follow-up visit, saving valuable resources and 
avoiding exposing patients to unnecessary investigations (8). Conclusions of a 2017 systematic 
review were that C-reactive protein was a promising tool for systematic screening for tuberculosis in 
HIV-infected adult populations (34). Availability of rapid, reliable, and inexpensive point-of-care 
tests would have obvious benefits in terms of facilitating earlier diagnosis, regardless of laboratory 
resources. 
4.3 Point of care (POC) C-reactive protein (CRP)  
POC CRP tests are widely used with a number of rapid, quantitative and semi-quantitative assays on 
the market. In 2014 a Cochrane Review concluded utility of POC C-reactive protein for guiding 
antibiotic therapy in patients with acute respiratory infections in primary health care settings (24), and 
the assay has been incorporated into management guidelines for suspected lower respiratory tract 
infection in high-income countries such as the UK (35).  
POC CRP testing is suited to low-resourced settings in terms of portability and convenience and has 
shown utility in improving the management of tuberculosis with associated cost savings.  In a South 
African study of HIV-infected smear-negative outpatients with suspected tuberculosis, Drain et al. 
demonstrated good sensitivity and moderate specificity of POC CRP combined with clinical criteria 
for improving diagnostic exclusion of tuberculosis (14). A Ugandan longitudinal study showed 
improved identification of HIV-infected participants requiring isoniazid preventive therapy for 
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tuberculosis when comparing the WHO symptom-screening algorithm with the addition of POC CRP 
testing against without POC CRP testing (36). The authors found a significant increase in the 
identification of those eligible for isoniazid preventive therapy and an associated decrease in referral 
for costly and time-consuming tuberculosis tests.  In a 2017 study, Yoon et al. found 89% sensitivity 
and 72% specificity for POC CRP in active screening for tuberculosis in ART-naïve, HIV-infected 
adults. (37).  
4.4 PCT testing in non-HIV infected populations 
Procalcitonin is a calcitonin precursor, stimulated by inflammatory cytokines and bacterial endotoxins 
from parenchymal tissues and an established early marker of bacterial infection (24, 25). In healthy 
controls, procalcitonin is undetectable. Concentrations are typically high in bacterial infection whilst 
normal or mildly elevated procalcitonin associated with viral infection is due to the inhibition of its 
release by viral stimulation of interferon-gamma release (38, 39).  Several studies have shown utility 
for procalcitonin for differentiating between systemic bacterial infection and viral infection in both 
immunocompetent and immunocompromised patients (25, 38, 40, 41), and between bacterial 
infection and systemic fungal infection (42). To date, the main utility of PCT testing for respiratory 
infections in non-HIV infected populations has been to rule-out bacterial infection, to aid appropriate 
antibiotic prescribing, and to predict severity of pneumonia and sepsis. Two Swiss randomized 
intervention trials of procalctionin-guided antibiotic use showed a 50% reduction in antibiotic 
exposure for patients presenting to emergency departments with lower respiratory infections (11), and 
a marked reduction in antibiotic prescription and duration in patients admitted with suspected CAP 
(12). A 2011 systematic review concluded that the use of procalcitonin to guide antibiotic therapy for 
respiratory infections was a safe and effective measure for reducing exposure to antibiotic therapy at 
all levels of care. (43). In contrast to bacterial infection, normal and moderately elevated procalcitonin 
concentrations have been observed in tuberculosis in non HIV-infected patients (26, 44).  
4.5 PCT testing in HIV-infected patients 
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Comparing studies of procalcitonin concentrations in HIV-infected and non-HIV infected individuals, 
a meta-analysis by Huang et al. (2014) noted higher procalcitonin concentrations in those with 
tuberculosis and HIV infection than in those with tuberculosis and without HIV (45). HIV-infected 
individuals with tuberculosis have been found to have moderately elevated concentrations (7, 46) 
compared to higher concentrations in CAP with HIV co-infection, and highest concentrations found in 
pneumococcal pneumonia (6, 7). In a study of immunocompromised patients in intensive care units 
(including 31/119 infection), procalcitonin was found to accurately rule-out bacterial infection at a 
cut-off of 0.5 ng/ml (41).  
4.6 POC procalcitonin testing 
POC procalcitonin testing is a relatively new development. The miniVIDAS B.R.A.H.M.S PCT® 
assay was a rapid, automated assay and forerunner of POC procalcitonin testing. Evaluation of the 
laboratory-based assay in a validation study found good accuracy and correlation with reference 
standards as well as utility in early diagnosis of bacterial sepsis (40). In 2016, the POC enzyme-linked 
assay system miniVIDAS® was utilized in a treatment algorithm in a study that demonstrated reduced 
antibiotic use in patients with exacerbation of chronic obstructive pulmonary disease (47). 
 
5. Literature review: utility of C-reactive protein and procalcitonin for differentiating between 
the tuberculosis, CAP and PJP in HIV-infected adults 
Whilst the utility of the two biomarkers for ruling-out tuberculosis and CAP has been described by a 
number of studies, our specific interest is in the utility of the two biomarkers for seriously ill 
hospitalised HIV-infected adults presenting with symptoms of respiratory infection of unknown 
aetiology. We conducted a broad systematic literature search for studies involving HIV-infected 
individuals with one or more of the target infections and C-reactive protein and/or procalcitonin 
testing.  
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The following databases were searched using title/abstract and no limitations of dates, type of study or 
site of study: MEDLINE, Cochrane, Scopus, Web of Science and Africawide through EBSCO. Using 
Boolean strategy and Mesh terms, terms searched were: (1) subjects (“HIV” OR “human 
immunodeficiency virus” OR “AIDS” OR “Acquired Immunodeficiency Syndrome”); (2) disease 
(“opportunistic infections” OR  "AIDS-Related Opportunistic Infections" OR “TB” OR 
“Mycobacterium” OR “MTB” OR “pneumocystis” OR “pjp” OR “pcp” OR “CAP” OR “pneumonia” 
OR “community acquired pneumonia” OR “Pneumonia, Pneumocystis" OR "Pneumocystis" OR 
"Pneumocystis jirovecii" OR "Pneumocystis carinii" OR "Pneumocystis Infections" OR 
"Tuberculosis" OR "Lung Diseases") and (3) tests (“PCT” OR “procalcitonin” OR “CRP” OR "C-
Reactive Protein"). Forward checking was conducted along with crosschecking of bibliographies of 
relevant articles. 
 This search yielded few studies, particularly comparing all three target infections; fewer still were 
conducted in high prevalence HIV and TB settings. Disparity in findings may be attributable to 
variability in populations, assays and research methodology. Relevant studies reporting C-reactive 










Table 1: Summary of studies reporting C-reactive protein and/or procalcitonin concentrations and/or diagnostic measures for tuberculosis (TB), bacterial 
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5.1 Diagnostic utility of procalcitonin  
We identified two studies that evaluated procalcitonin in all three target infection. One South African 
study by Nyamande et al. compared procalcitonin concentrations in HIV-infected patients and found 
statistically significant differences in procalcitonin concentrations between the three target infections; 
however, no diagnostic accuracy measures were reported (6). The second by Schleicher et al. (also 
South African), involved bacterial pneumonia and tuberculosis, and demonstrated 82% sensitivity and 
82% specificity at a cutoff value of 3 ng/ml. for discriminating pneumococcal pneumonia from 
tuberculosis (7). Both studies based participant selection on suspected CAP, and tuberculosis may 
have been underrepresented in analyses.  
5.2 Diagnostic utility of C-reactive protein  
Several studies report comparative C-reactive protein concentrations in HIV-infected patients with 
respiratory infections; although ranges differ widely, there is a general consensus that the highest 
concentrations are found in CAP compared to tuberculosis or PJP (7, 29, 30, 48).  Conversely, a 1999 
Danish study (27) failed to demonstrate a significant difference in C-reactive protein concentrations 
between CAP and PJP using a cut-off value of ≥80 mg/L.  
We identified only two studies reporting diagnostic accuracy measures in all three of the target 
infections, with conflicting findings. A British case notes review study of HIV-infected adults 
admitted with respiratory infections found poor specificity in C-reactive protein for discriminating 
between the three infections (48), whereas a Spanish study found higher specificity (83%), and 
sensitivity 69%, for combined CRP and IL-8, in discriminating bacterial pneumonia from PJP or 
mycobacterial infections.  The cohort included hospital-acquired infections and other mycobacterial 
infections beside tuberculosis (49). 
A further two studies looked at two out of three of the target infections (7, 29). The first study by 
Cilloniz et al. involved 331 HIV-infected adults hospitalised with suspected CAP who were diagnosed 
with the following: bacterial and viral pneumonias, PJP, mixed infection, and unknown aetiology. The 
authors reported 35% sensitivity, 87% specificity at a cutoff value of 220 mg/L for predicting CAP, 
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and 74% sensitivity, 53% specificity at a cutoff value of 120 mg/L for predicting PJP (29). The other 
study by Schleicher (as for procalcitonin above) found sensitivity 79% and specificity 82% at a cutoff 
value of 246 mg/L in discriminating pneumococcal CAP from tuberculosis (7). Participant selection 
for both studies was based on patients presenting with suspected CAP. 
5.3 Challenges to evaluation of biomarker diagnostic utility   
Infection with more than one respiratory pathogen routinely presents a challenge to diagnostic 
research; dual or co-morbid infection is not uncommon. Cilloniz et al. found concomitant CAP and 
PJP infection in 17% (38/227) of participants (29). Nyamande et al. identified mixed infection in 21% 
(36/169) of participants in whom aetiology was determined, with higher mean procalcitonin 
concentrations in patients with tuberculosis/bacterial co-infection than in those with tuberculosis 
alone (6). 
Disparity in procalcitonin response to different bacterial organisms may also limit ability of 
procalcitonin to differentiate between respiratory CAP and PJP. Nayamande found overlapping ranges 
between patients with atypical bacterial pneumonia and patients with PJP, consistent with a number of 
studies that report lower PCT concentrations in patients with atypical or Gram-negative infections (6, 
12, 50). Furthermore, because patients are often commenced on antibiotics before attending higher 
facilities, changes in C-reactive protein concentrations in response to antibiotic therapy may impact 
findings (30).  
 
6. Conclusion  
Diagnosing and discriminating between respiratory infections of different aetiologies in the setting of 
HIV remains a challenge. Improved diagnostic algorithms using assays that are suited to low-resource 
settings would contribute to reducing delay to diagnosis and initiation of appropriate treatment. 
Although C-reactive protein and procalcitonin have shown some promise for discriminating between 
different respiratory infections in HIV-infected individuals, their performance is incompletely defined 
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and further studies are needed to evaluate their potential. Our overall hypothesis is that C-reactive 
protein and/or procalcitonin may have discriminative value as part of an improved algorithm in the 
triage of HIV-infected inpatients with respiratory infections; this study is designed to explore 
diagnostic utility of each biomarker as an initial step. For this purpose, we propose a secondary 
analysis of a large prospective HIV-infected cohort, recruited from two secondary level hospitals in 
Cape Town South Africa, serving communities with high HIV and TB prevalence. Patient enrollment 
was based on the 2007 WHO algorithm for seriously ill inpatients with suspected tuberculosis, but 
expanded to include cough of any duration in light of previous study findings, and reflects the 
population for whom the two biomarkers are being evaluated.  
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Appendix 2: 2016 WHO algorithm for managing people living with HIV and suspected of having TB 


















a For all people with unknown HIV status, HIV testing should be performed according to national guidelines. 
b Suspicion of TB is defined by the presence of any one of the following symptoms. 
   - For adults and adolescents living with HIV: current cough, fever, weight loss or night sweats. 
   - For children living with HIV: poor weight gain, fever, current cough or history of contact with a TB case. 
c Danger signs include any one of the following: respiratory rate>30 per minute, temperature >39oC, heart    rate >120 
beats per minute and unable to walk unaided. 
d For people suspected of having extrapulmonary TB, extrapulmonary specimens shoud be obtained for Xpert MTB/RIF 
(cerebrospinal fluid, lymph nodes and other tissues: Xpert MTB/RIF has low sensitivity for pleural fluid and data are 
limited for stool, urine or blood). The urine lateral flow lipoarabinomannan (LF-LAM) assay may be used to assist in 
diagnosing active TB among seriously ill adults and children living with HIV, regardless of CD4 count. 
e Antibiotics with broad-spectrum antibacterial activity (except fluoroquinolones) should be used.  
f If Xpert MTB/RIF shpws rifampicin resistance, treatment for multidrug-resistant TB  should be initiated. If the person is 
considered at low risk for rifampicin resistance, a second Xpert MYB/RIF test should be performed on a fresh specimen.  
Collect and refer a sample for culture and additional drug sensitivity testing.  
g If Xpert MTB/RIF shows negative results, the test can be repeated using a fresh specimen.  
h Further investigations for TB include chest x-ray, clinical assessment, a repeat Xpert MTB/RIF on a fresh specimen and 
culture. If extrapulmonary TB is suspected, extrapulmonary specimens should be obtained and sent for culture and 
abdominal ultrasound may be performed. 
I ART should be recommended for adults, regardless of CD4 count or clinical stage. 
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Tuberculosis, bacterial community-acquired pneumonia (CAP), and Pneumocystis jirovecii 30	
pneumonia (PJP) are major causes of hospitalisation in HIV-infected individuals. Prompt diagnosis 31	
and treatment initiation are important to reduce morbidity and mortality, but are hampered by limited 32	
diagnostic resources in resource-poor settings. C-reactive protein (CRP) and procalcitonin have shown 33	
diagnostic utility for respiratory tract infections, however few studies have focussed on their ability to 34	
distinguish between tuberculosis, CAP, and PJP in HIV-infected inpatients. 35	
 36	
We evaluated the diagnostic accuracy of CRP and procalcitonin, compared with composite reference 37	
standards, to discriminate between the three target infections in adult HIV-infected inpatients in two 38	
district level hospitals in Cape Town, South Africa, admitted with current cough and danger signs in 39	
accordance with the WHO algorithm for tuberculosis in seriously ill HIV-infected patients. Study 40	
clinicians were blinded to CRP and procalcitonin results. 41	
 42	
248 participants met study case definitions: 133 with tuberculosis, 61 with CAP, 16 with PJP, and 38 43	
with mixed infection. The differences in median CRP and procalcitonin concentrations between the 44	
three infections were statistically significant, but distributions overlapped considerably. CRP and 45	
procalcitonin cut-offs with sensitivities of ≥ 90% were found for all three target infection pairs, 46	
however corresponding specificities were low. Receiver operating characteristic areas under the curve 47	
for CRP and procalcitonin were between 0.68 and 0.74 for PJP versus tuberculosis and PJP versus 48	
CAP.  49	
 50	
CRP and procalcitonin showed limited value in discriminating between the three target infections due 51	
to widely overlapping distributions, but diagnostic accuracy was higher for discriminating PJP from 52	
CAP or tuberculosis.  Our findings suggest that CRP and procalcitonin may have greater diagnostic 53	





Respiratory infections are a major cause for hospital admission in HIV-infected people globally in the 58	
antiretroviral era; the commonest being tuberculosis, bacterial community-acquired pneumonia 59	
(CAP), and Pneumocystis jirovecii pneumonia (PJP) (1). Prompt diagnosis and initiation of 60	
appropriate treatment is important to reduce mortality in HIV-infected inpatients.  61	
Determining the aetiology of serious infections in inpatients with HIV is challenging, in part due to 62	
considerable overlap in the clinical and radiographic presentation of tuberculosis, CAP, and PJP (2). 63	
Atypical presentation and dual infection further compounds these diagnostic challenges. Furthermore, 64	
there are limitations of current diagnostic methods and limited access to diagnostic tests in resource 65	
poor settings (3, 4, 5).  66	
WHO’s algorithm for the diagnosis of tuberculosis in seriously ill patients (6) recommends broad 67	
spectrum antibiotics, that treatment for PJP should be considered (without giving guidance on 68	
selection of patients for empiric PJP therapy), using a rapid nucleic acid amplification test (the Xpert 69	
MTB/RIF assay) to diagnose tuberculosis, and empiric therapy for tuberculosis if the Xpert MTB/RIF 70	
assay is negative or unavailable and there is no response to antibiotics. Our group recently reported 71	
that 91.5% of patients defined as seriously ill by WHO and who had a current cough were diagnosed 72	
with tuberculosis, CAP, and/or PJP (7). Simple affordable tests to discriminate between these three 73	
infections could improve outcomes in seriously ill patients. Previous studies have proposed the use of 74	
biomarkers of inflammation as triage tests in clinical algorithms. Two of these, C-reactive protein 75	
(CRP) and procalcitonin, have shown some diagnostic utility for bacterial respiratory infections (8, 9). 76	
An additional advantage is that both CRP and procalcitonin are available as affordable point-of-care 77	
tests (10, 11).  C-reactive protein is a non-specific acute phase protein released by the liver in response 78	
to inflammatory cytokines (12). Typically, significantly higher serum concentrations are found in 79	
bacterial compared to viral infection (13), and low to modest concentrations have been reported in 80	
patients with PJP (14). CRP has shown high sensitivity but low specificity for diagnosing HIV-81	
associated tuberculosis (8).  82	
Procalcitonin is a calcitonin precursor, stimulated by inflammatory cytokines and bacterial endotoxins 83	
from parenchymal tissues and an established early marker of bacterial infection (12, 13). 84	
	 4	
Studies have shown utility for procalcitonin for differentiating between systemic bacterial infection 85	
and viral infection (13, 15), and between bacterial infection and systemic fungal infection (16). 86	
However, only two studies have examined diagnostic performance of CRP in discriminating between 87	
tuberculosis, CAP, and PJP in hospitalised patients with HIV, with conflicting results (17, 18). We 88	
were unable to find any studies reporting diagnostic accuracy of procalcitonin in discriminating 89	
between all three infections.  90	
The purpose of this study was to explore the diagnostic accuracy of CRP and procalcitonin in 91	
predicting presence or absence of each of the three major infections in seriously ill inpatients with 92	
HIV infection. Secondary objectives were to describe the extent to which CRP and procalcitonin 93	
concentrations differed between the three infections and to determine optimal concentration cut-offs 94	




Study Setting and Participants 99	
We conducted a secondary analysis of a sub-set of prospective cohort data from a larger study (7), 100	
which was designed to improve the evidence base for the WHO algorithm for the diagnosis of 101	
tuberculosis in seriously ill HIV-infected participants with current cough (3). Recruitment for the main 102	
study took place at two secondary level hospitals in Cape Town, South Africa, serving communities 103	
with high HIV and tuberculosis prevalence: G.F. Jooste District Hospital from November 2011 until 104	
the hospital’s closure in February 2013, and Khayalitsha District Hospital from March 2013 until 105	
October 2014.  106	
 107	
Inclusion criteria for the main study were: admission into the enrollment facility within the previous 108	
24 hours,  ≥18 years of age,  known HIV infection, cough of any duration, and at least one WHO-109	
defined danger sign (respiratory rate >30/min, fever >39o C, pulse rate >120/min, and unable to walk 110	
unaided). Exclusion criteria were: current, recent, or defaulted anti-tuberculosis treatment; 111	
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exacerbation of either congestive cardiac failure or chronic obstructive pulmonary disease; and failure 112	
to provide a spontaneous or induced sputum specimen.  113	
 114	
For the current study we added the following two inclusion criteria: 1) participants fulfilling our case 115	
definitions for tuberculosis, CAP, and/or PJP, and 2) participants with both a CRP and procalcitonin 116	
test result (assays done in a batch at the end of the study).  117	
 118	
Case definitions  119	
1) Tuberculosis: positive Mycobacterium tuberculosis culture from any site plus at least one symptom 120	
consistent with tuberculosis (cough, fever, night sweats, weight loss).  121	
2) CAP: cough ≤ 14 days plus one or more additional respiratory symptoms (sputum, breathlessness, 122	
chest pain, haemoptysis or fever) plus radiological evidence of pulmonary consolidation (confirmed 123	
by a radiologist) (19).  124	
3) PJP: cough ≤ three months plus radiological evidence of diffuse bilateral interstitial infiltrates 125	
(confirmed by a radiologist) plus oxygen saturation ≤ 92% (adapted from Centers for Disease Control 126	
and Prevention case definition) (20). 127	
 128	
Investigations 129	
Three sputum specimens were obtained from each participant. One sample was sent for Gram stain, 130	
culture, and sensitivity, and two samples for smear examination with auramine staining for acid-fast 131	
bacilli (AFB) and liquid mycobacterial culture (BACTECTM MGITTM 960; Becton, Dickinson and 132	
Company, New Jersey, USA). Mycobaterial blood culture was done on all participants. Mycobacterial 133	
culture was done on other specimens when appropriate (e.g. pleural fluid). 	Serum β-D-glucan assay 134	
(FungitellTM; Associates of Cape Cod, Inc., east Falmouth, MA, USA)	was done on all participants.  135	
 136	
CRP and procalcitonin tests were done on stored serum in a batch after the study, therefore these tests 137	
had no role in patient management. Laboratory staff were blinded to participant diagnosis and 138	
outcome. Assays used were: Siemens Advia 1800 for CRP and Siemens Advia Centaur XP for 139	
	 6	
procalcitonin. Assay range for CRP was 4-[304-336] mg/L, normal range was below 10 mg/L. Assay 140	
range for procalcitonin was <0.02-75 µg/L, normal range below 0.02 µg/L. 141	
Chest radiographs were performed on admission and retrospectively reviewed by a senior radiologist 142	
blinded to diagnoses and results of laboratory investigations.  143	
	144	
Statistical analyses 145	
All analyses were performed using Stata software version 13.0 (StataCorp Inc, College Station, Texas, 146	
USA).  147	
 148	
Based on our fixed sample size, we explored precision to detect 90% sensitivity for each index test for 149	
the three target infections, aiming for a maximum ±10% variation in 95% confidence intervals (CIs). 150	
We were unable to find data on sensitivity estimates for procalcitonin in all three target infections in 151	
HIV-infected individuals,  therefore calculations were based exclusively on studies reporting CRP 152	
measures of diagnostic accuracy. We estimated a range of confidence intervals of binomial 153	
proportions using the Wilson-score interval for smaller sample sizes (21). Since our data was not 154	
normally distributed, a second calculation was made using 85% of the original sample sizes as 155	
suggested by Lehmann et. al (22). We estimated the 95% CIs of  90% sensitivity to be 83%-94% for 156	
tuberculosis, 79%-96% for CAP, and 69%-99% for PJP. The small sample size for PJP accounted for 157	
wide 95% confidence intervals. Further details of these sample size calculations are provided in table 158	
S1. 159	
To detect differences in CRP concentrations between the three target infections, we estimated power 160	
for a two-sample means test (assuming unequal variances), based on relevant literature. (Expected 161	
means for CRP were approximate due to lack of reported standard deviations for tuberculosis or 162	
CAP). Our study had 80% power and alpha of 0.05 (using 85% of the original sample size to account 163	
for non-normal distribution of CRP and procalcitonin concentrations) to detect a minimum mean 164	
concentration difference in CRP between tuberculosis and PJP of 36%, between CAP and PJP of 14%, 165	
and between CAP and tuberculosis of 14%, and a minimum mean concentration difference in 166	
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procalcitonin of 50% between tuberculosis and PJP, 62% between CAP and PJP, and 62% between 167	
CAP and tuberculosis. Further details of these sample size calculations are provided in table S2. 168	
 169	
Diagnostic accuracy analyses for CRP and procalcitonin were performed for  participants fulfilling 170	
criteria for one of the three single infection definitions. Participants with mixed infection were 171	
analysed separately. In clinical practice, differential diagnostic challenges usually present between two 172	
of the target infections and less commonly between all three, hence we calculated diagnostic accuracy 173	
measures between infection pairs in addition to each target infection versus the other two. 174	
 175	
As distributions of both CRP and procalcitonin were not normally distributed, we used non-parametric 176	
statistical tests for continuous variables. Univariate associations between participant baseline 177	
characteristics in infection pairs were analysed using the Wilcoxon-Mann-Whitney test for continuous 178	
data, and Chi-square test (or Fisher’s Exact test if values in a cell were <5), for categorical data. All P 179	
tests were two-tailed. 	180	
For biomarker analyses, CRP and procalcitonin values below the detectable limit (BDL) of the assay 181	
were substituted with half BDL (in preference to substitution with the assay limit or with zero, both of 182	
which have been shown to bias parameter estimates) (23).   183	
 184	
Receiver Operating Characteristic (ROC) area under the curve (AUC) analyses were used to explore 185	
potential cut-offs for CRP for each target infection using Liu’s index (24), which we then used to 186	
calculate diagnostic accuracy estimates. Cut-offs were also explored using the WHO 90% sensitivity 187	
recommendation for screening tests for tuberculosis (25). To mitigate overfitting and improve 188	
accuracy of model prediction, we performed cross-validation on all ROC AUC’s exceeding 60% using 189	
k-fold cross-validation, as the dataset was too small for generation of a training set.  190	
Since there are few studies on the diagnostic accuracy of procalcitonin for infections in HIV-infected 191	
patients, we explored cut-offs established for both lower respiratory tract infections (LRTI) and sepsis. 192	
Procalcitonin categories for LRTI were:  < 0.1 µg/L, bacterial infection very unlikely;  0.1 - 0.25 193	
µg/L, localised bacterial infection unlikely;  0.25 - 0.5 µg/L, localised bacterial infection possible;  > 194	
	 8	
0.5 µg/L, suggestive of bacterial infection. Procalcitonin categories for systemic bacterial infection / 195	
sepsis were: 0.5 – 2 µg/L, systemic infection possible;  2 – 10 µg/L, suggestive of systemic infection;  196	
> 10 µg/L, severe systemic infection / septic shock (9). 197	
 198	
Ethics  199	
The University of Cape Town human research ethics committee approved both main and current 200	
studies (HREC REF 334/2011, renewal dates: 30/05/2016 and 30/11/2018). Participants who met 201	
inclusion criteria were invited to participate in the study and written informed consent obtained. 202	
Participants who were admitted in a confused state were enrolled and offered the option of remaining 203	
in the study once orientated.  204	
 205	
This study conforms to the Standards for Reporting Diagnostic Accuracy Studies (STARD) guidelines 206	





500 participants were screened for this study. 4 participants without danger signs and 84 enrolled prior 212	
to biomarker testing were excluded from the current study. A further 12 participants with missing 213	
index test results and 58 participants without radiological reviews were also excluded. The other 72 214	
participants received empirical diagnoses of one or more of the three target infections, but did not 215	
meet study case definitions. Ten participants were excluded due to diagnoses other than the three 216	
target infections (meningitis, disseminated Cryptococcus, emmonsia, bronchitis, and post-TB 217	
bronchiectasis with a pneumothorax).  218	



































2054 patients screened 
for main study  
Inclusion criteria:  
Age ≥ 18 years 
HIV-seropositive 
No current /recent TB 
therapy 
Consent 
Cough of any duration 
One or more WHO danger 
signs1 
Sputum sample obtained 
1570 excluded: 
Use of anti-tuberculosis therapy:  
    653 current  
    30 completed < 1 month previously  
    50 defaulted in past 6 months  
HIV status: 
    392 HIV-negative  
    47 refused HIV test on admission 
7 previous enrolment in study  
63 no consent 
18 <18 yrs old  
104 no cough:  
128 no danger signs  
26 no sputum sample obtained  
28 exacerbation of chronic obstructive pulmonary 
disease  
24 exacerbation of congestive cardiac failure  
 
484 eligible for this study   
400 with biomarker test performed 
 
84 excluded: 
enrolled prior to biomarker 
test collection period 
 
	Clinical & laboratory assessment/ 
Reference standards performed on 388 140 excluded from primary 
analysis: 
58 without radiological review 
72 not meeting full case 
definitions 
10 with other definitive 
diagnoses 
248 included in primary analysis  
12 excluded patients: 
Missing biomarker test results: 
C-reactive protein2 (n= 8) 
Procalcitonin3 (n= 12) 
C-reactive protein + 
procalcitonin (n=8) 
 
388 with biomarker test results 
 
1	WHO	danger	signs:	respiratory rate >30 /min, fever >39oC, pulse rate >120 /min or 
unable to walk unaided.	
	 10	
Figure 2 summarises distribution of target infections in 210 participants with one of the three target 253	
infections. All participants had received at least one dose of antibiotics use prior to obtaining blood 254	
samples for biomarker tests. 73/248 (29%) reported taking cotrimoxazole prophylaxis prior to 255	
admission. Univariate analysis of variables associated with each of the three single infection diagnoses 256	
are shown in table 1. Tuberculosis was statistically associated with lower haemoglobin concentrations 257	
and reported weight loss compared with the other two groups. Inability to walk unaided was more 258	
common in those with tuberculosis than in those with CAP. Those with CAP had statistically higher 259	
median white cell count and CD4 count than the other two infections. The CAP group was more likely 260	
to have been using antiretroviral therapy prior to admission compared with the tuberculosis group. 261	
Participants with PJP had statistically lower CD4 counts, and were more likely to have a respiratory 262	




Figure 2. Number of participants diagnosed with single target infections and mixed infections.  267	
Tuberculosis (PTB), bacterial community acquired pneumonia (CAP) and Pneumocystis jirovecii  268	












































P-value for pairwise comparison* 










TB vs. CAP: 0.96, CAP vs. PJP: 0.84    
PJP vs. TB: 0.75 
 
Sex: female n(%) 139 (66) 84 (63) 44(72) 11(69) TB vs. CAP: 0.22, CAP vs. PJP: 0.71#   




60 (29) 38(29) 18(30) 4(25) TB vs. CAP: 0.89, CAP vs. PJP: 0.49#    
PJP vs. TB: 1.00# 
 
Antiretroviral 
therapy n (%) 
76 (36) 43(32) 29(48) 4(25) TB vs. CAP: 0.04, CAP vs. PJP: 0.16# 
PJP vs. TB: 0.78#   
   










TB vs. CAP: 0.0001 












TB vs. CAP:  0.0001, CAP vs. PJP: 0.01 
PJP vs. TB: 0.5 
 










TB vs. CAP: 0.0001, CAP vs. PJP: 0.24 
PJP vs. TB: 0.0001 
  
β-D-glucan > 300 
pg/mL 
25 (12) 11 (8) 1 (2) 13 (80) TB vs. CAP: 0.11#, CAP vs. PJP: 
<0.0001# PJP vs. TB: <0.0001# 
 
WHO danger signs1:      
Pulse rate> 
120beats/min 
166 (79) 106 (80) 51 (84) 9 (56) TB vs. CAP: 0.52 , CAP vs. PJP: 0.02   




137(65) 83 (62) 38 (62) 16 (100) TB vs. CAP: 0.99 , CAP vs. PJP: 0.002#  




31 (15) 20 (15) 10 (16) 1 (6) TB vs. CAP: 0.81, CAP vs. PJP: 0.44#   
PJP vs. TB: 0.47# 
 
Unable to walk 
unaided  
119 (57) 88 (67) 23 (38) 8 (50) TB vs. CAP:<0.0001, CAP vs. PJP: 0.40  
PJP vs. TB: 0.19   
TB symptoms2: 










TB vs. CAP: 0.58 , CAP vs. PJP:1.00# 






130 (98)             
 




TB vs. CAP: 0.005# , CAP vs. PJP: 0.43#  













TB vs. CAP: 0.29, CAP vs. PJP: 0.27# 
PJP vs. TB: 0.74# 
 
Abbreviations: TB, tuberculosis; CAP, bacterial community-acquired pneumonia; PJP, Pneumocystis jirovecii pneumonia; Hb: 
haemoglobin; WCC: white cell count 
*Hypothesis tests- Wilcoxon-Mann-Whitney test for continuous data; Chi-square test for categorical data. #Fisher’s exact test where 1 or 
more cells <5   
1 Danger signs based on WHO algorithm for diagnosis of TB in seriously ill patients; 2Cough of any duration was a study inclusion 
criterion   
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CRP concentrations and diagnostic utility for each infection 287	
Distributions of CRP concentrations by single infection category are shown in figure 3A. Comparison 288	
of CRP concentrations between the three single infections are shown in table 2. Elevated 289	
concentrations (>10mg/L) were found in 206/210 (98%) participants: 131/133 (98%) with 290	
tuberculosis, 60/61 (99%) with CAP, and 15/16 (94%) with PJP. There were statistically significant 291	
differences in median concentrations between infection pairs, with considerable overlap in 292	
distributions. The highest concentrations were in participants with CAP and the lowest concentrations 293	
in those with PJP.  294	
 295	
Figure	3.	Distribution of (A) C-Reactive Protein and (B) procalcitonin by diagnosis.  296	













Table 2: C-reactive protein and procalcitonin distributions by infection in 210 participants with a 309	




ROC AUCs for CRP for each disease pair versus the other two are shown in figure 4. Cross-validation 314	
showed minor reductions of ROC AUCs, from 0.60 to 0.58 (95% CI : 0.49-0.67) in the tuberculosis 315	
versus CAP group; from 0.74 to 0.72 (95% CI: 0.59-0.84) for CAP versus PJP; and from 0.68 to 0.64 316	
(95% CI: 0.51-0.77) for PJP versus tuberculosis. Diagnostic accuracy estimates for two cut-offs for 317	
each infection pair and each infection versus the other two infections are presented in table 3. CRP 318	
cut-offs with reasonable diagnostic accuracy were found for PJP versus CAP, PJP versus tuberculosis 319	



































TB vs.CAP: 0.02, CAP vs. PJP: 0.003 
PJP vs. TB: 0.02 
      
CRP ≥10mg/L1 n (%) 206 (98) 
 
131 (98.5) 60 (98.4) 15 (93.8) TB vs.CAP: 1.00#, CAP vs. PJP: 0.38# 
PJP vs. TB: 0.29# 
 




0.7 (0.4-2.1) 2.0 (0.4-5.2) 0.2 (0.1-1.3) TB vs. CAP: 0.05, CAP vs. PJP: 0.01 
PJP vs. TB: 0.05 
 
PCT ≥0.02 µg/L2: n (%) 209 (99.5)) 132 (99) 61 (100) 16 (100) - 
      
PCT ≥0.1 µg/L: n (%) 199 (94.8) 
 
128 (96.2) 58 (95.1) 13 (81.3) TB vs. CAP: 0.71#,, CAP vs. PJP: 0.10# 
PJP vs. TB: 0.04# 
 
PCT ≥0.25 µg/L: n (%) 
 
 
170 (81) 112 (84) 50 (82) 8 (50) TB vs. CAP: 0.70, CAP vs. PJP: 0.008 
PJP vs: TB: 0.001 
PCT ≥0.5 µg/L: n (%) 137 (65.2) 
 
87 (65.4) 43 (70.5) 7(43.8) TB vs. CAP: 0.49, CAP vs. PJP: 0.05 
PJP vs. TB: 0.11 
 
PCT ≥2 µg/L : n (%) 69 (32.9) 36 (27.1) 30 (49.2) 3 (18.8) TB vs. CAP: 0.003, CAP vs. PJP: 0.05# 
PJP vs. TB: 0.56# 
 
PCT >10 µg/L: n (%) 
 
16 (8) 8 (6) 8 (13) 0 (0) -  
Abbreviations: CRP, C-reactive protein; PCT, Procalcitonin; TB, tuberculosis; CAP, bacterial community acquired pneumonia; PJP, 
Pneumocystis jirovecii pneumonia 
1 Elevated concentration. 2Lower detectable limit for procalcitonin assay.  
*Hypothesis tests- Wilcoxon-Mann_Whitney test for non-normally distributed continuous data and Chi-square test for categorical data. #Fisher’s 
exact test where 1 or more cells <5 . 
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Figure 4. ROC curves for C-reactive protein and procalcitonin for each diagnosis within infection 324	
pairs.  325	
(A) Tuberculosis versus bacterial community acquired pneumonia, (B) community-acquired bacterial 326	
pneumonia versus Pneumocystis jirovecii pneumonia, and (C) Pneumocystis jirovecii pneumonia 327	
versus tuberculosis. 328	
C-reactive protein (CRP), procalcitonin (PCT), and area under the receiver operating characteristic 329	










Table 3: Diagnostic accuracy of C-reactive protein for target infections.  339	
Two cut-offs are listed for each infection pair and one infection versus the other two: the first with  340	




Procalcitonin concentrations and diagnostic utility for each infection 345	
Distributions of procalcitonin category in each of the three target infections are shown in figure 3B 346	
and table 2. We found highest procalcitonin concentrations in the CAP group and lowest in those with 347	














































 CRP <175 65.4      
(56.7-73.4) 
57.4     
(44.1-70.0) 
1.53       
(1.12-2.11) 
0.60       
(0.44 -0.83) 





CRP ≥ 63  90.2      
(79.8- 96.3) 
18.8      
(4.0-45.6) 
1.11      
(0.86-1.42) 





 CRP ≥ 147 63.9      
(50.6-75.8) 
87.5     (61.7-98.4) 5.11       
(1.38-18.96) 
0.41       
(0.28-0.60)  
 
12.41       
(2.83-59.7) 
PJP vs.   
TB 
 
CRP ≥33  93.8      
(69.8-99.8) 
2.3       
(0.5-6.5) 























CRP ≥64 90.2      
(83.9-94.7) 
13.0       
(6.4-22.6) 
1.04       
(0.94-1.15) 
0.75       
(0.35-1.63) 
1.38       
(0.58-3.25) 
 CRP ≥150 48.9      
(40.1-57.7) 
 
49.4      
(37.8-61.0) 
 
0.96       
(0.73-1.28) 
1.04       
(0.78-1.37) 





CRP ≥63 90.2 
(79.8-96.3) 
10.7       
(6.3-16.9) 
1.01       
(0.91-1.12) 
0.92       
(0.38-2.23) 
1.10       
(0.42-2.87) 
 CRP ≥175 57.4      
(44.1-70.0) 
67.8      
(59.6-75.2) 
1.78       
(1.30-2.45) 
0.63       
(0.46-0.86) 





CRP ≥33 93.8      
(69.8-99.8) 
2.6      
(0.8-5.9) 
0.96       
(0.85-1.09) 
















(1.99- 36.55)  
  
 
Abbreviations:  TB, tuberculosis; CAP, bacterial community acquired pneumonia; PJP, Pneumocystis jirovecii pneumonia; PPV, positive 
predictive value; NPV, negative predictive value; LR, Likelihood ratio; CI, confidence interval. *Cohort prevalences: TB, 63,3% (95%CI, 
56.4%-69.9%);  CAP, 29.0% (95% CI, 23.0%-35.7%); PJP,  7.6% (95% CI, 4.4%-12.1%) 
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the three infection groups, but there was marked overlap in distributions. Diagnostic performance of 349	
procalcitonin categories for discriminating between infection pairs is shown in table 4. ROC AUCs for 350	
procalcitonin for each disease pair versus the other two are shown in figure 4. Best performance of 351	
procalcitonin was in discriminating between  352	
CAP and PJP. 353	
Table 4: Diagnostic accuracy of procalcitonin by category for target infection pairs.  354	
Selected categories are based on assay guidelines developed for antibiotic use guidance in lower  355	


























PCT ≥0.1 96.2      
(91.4-98.8) 
4.9       
(1.0-13.7) 
1.01      (0.95-
1.08) 
0.76      (0.19-
3.10) 
1.32       
(0.34-5.21) 
 
 PCT ≥0.25 84.2      
(76.9-90.0) 
18.0       
(9.4-30.0) 
 
1.03      (0.89-
1.18) 
0.88      (0.45-
1.70) 
1.17       
(0.53-2.59) 
 PCT ≥0.5 65.4      
(56.7-73.4) 
29.5      
(18.5-42.6) 
0.93      (0.76-
1.14) 
1.17      (0.75-
1.84) 
0.79       
(0.41-1.52) 
 




0.55      (0.38-
0.80) 





 PCT >10# 6.0       
(2.6-11.5) 
86.9      
(75.8-94.2) 
 
0.46      (0.18-
1.16) 
1.08      (0.97-
1.20)  
 
0.42       
(0.16-1.15) 
       
CAP vs. 
PJP 
PCT ≥0.1 95.1      
(86.3-99.0) 
18.8      
(4.0-45.6) 
1.17      (0.92-
1.49) 
0.26      (0.06-
1.180 
4.46       
(0.92-21.84) 
 
 PCT ≥0.25 82.0     
(70.0-90.6) 
 
50.0     
(24.7-75.3) 
1.64      (0.99-
2.71) 
0.36      (0.17-
0.75) 
4.55       
(1.44-14.43) 
 PCT ≥0.5 70.5     
(57.4-81.5) 
56.2      
(29.9-80.2) 
1.61      (0.90-
2.87) 
0.52      (0.29-
0.94) 
3.07       
(1.02-9.26) 
 




2.62      (0.92-
7.51) 





       
PJP vs. 
TB 
PCT ≥0.1 81.2      
(54.4-96.0) 
3.8      
(1.2-8.6) 
0.84      (0.67-
1.07) 
4.99      (1.31-
18.94) 
0.17       
(0.04- 0.71) 
 
 PCT ≥0.25 50.0      
(24.7-75.3) 
 
15.8      
(10.0-23.1) 
0.59      (0.36-
0.97) 
3.17       
(1.69-5.93)  
 
0.19       
(0.07-0.54) 
 PCT ≥0.5 43.8      
(19.8-70.1) 
 
34.6      
(26.6-43.3) 
 
0.67      (0.38-
1.18)  
 
1.63      (1.00-
2.66) 
0.41       
(0.15-1.14) 
 




0.69      (0.24-
1.99) 





Abbreviations:  TB, tuberculosis; CAP, bacterial community acquired pneumonia; PJP, Pneumocystis jirovecii pneumonia; PPV, positive 
predictive value; NPV, negative predictive value; LR, Likelihood ratio; CI, confidence interval. *Cohort prevalences: TB, 63,3% 
(95%CI, 56.4%-69.9%);  CAP, 29.0% (95% CI, 23.0%-35.7%); PJP,  7.6% (95% CI, 4.4%-12.1%) 
#Analaysis of PCT category of >10 was only performed in TB vs. CAP infection pairs as no PJP participants had PCT exceeding 10µg/L. 
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Participants with mixed infection 359	
Analysis of baseline characteristics and index test concentrations for those with mixed infection 360	
compared with those with single target infections are summarised in table S3. Analysis of both 361	
biomarkers showed wide distributions, overlapping with those of the three mono-infections. Elevated 362	
CRP was found in all 38 participants with mixed infections. Both CRP and procalcitonin medians 363	
were statistically higher in the mixed infection group compared with the PJP group. 3 participants had 364	
procalcitonin concentrations <0.1 µg/L, all of whom had CAP dual infection (two with tuberculosis 365	
and the other with PJP). Procalcitonin ≥0.25 µg/L captured 29/37 (78.4) with CAP dual infection, ≥ 366	
0.5 µg/L captured 23/37 (62.2%),  and 14 (37.8%) exceeded the ≥2 µg/L cut-off, 3 of whom had 367	




We evaluated the diagnostic accuracy of CRP and procalcitonin for differentiating between the three 372	
major infections affecting HIV-infected adult inpatients using a case-referent enrollment study design. 373	
Our study was one of only a very few to assess the diagnostic accuracy of CRP and procalcitonin for 374	
the three commonest infections in HIV-infected inpatients. We found statistically significant 375	
differences in median CRP and procalcitonin concentrations between the three infection groups, but 376	
there was marked overlap in distributions. Participants with PJP had lower CRP and procalcitonin 377	
concentrations. Procalcitonin and CRP had ROC AUCs of around 0.7 for discriminating PJP from 378	
CAP and tuberculosis in pairwise comparisons, indicating moderate discrimination, but both 379	
biomarkers performed less well in discriminating CAP from tuberculosis. A CRP cut-off of 147 mg/L 380	
had high specificity for discriminating PJP from CAP, and high sensitivity for discriminating PJP 381	
from tuberculosis. We found cut-offs with sensitivities of 90% or more for CRP for all three target 382	
infection pairs, and for procalcitonin for two target infection pairs (tuberculosis versus PJP and CAP 383	
versus PJP), but specificities were much lower than the 70% recommended by WHO for tuberculosis 384	
screening tests (20). Our findings suggest that CRP and/or procalcitonin should be explored in the 385	
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development of clinical prediction rules in seriously ill HIV-infected patients or in a panel of 386	
biomarkers.   387	
 388	
Previous studies have demonstrated the diagnostic value of CRP in active tuberculosis case detection 389	
in otherwise healthy HIV-infected persons, however higher false positive rates were found in passive 390	
case detection (8).  Elevated CRP is known to occur in all three of our target infections in individuals 391	
with HIV, and our finding that CRP concentrations were highest in CAP, follwed by tuberculosis, and 392	
lowest in PJP, is consistent with previous studies (17, 18, 27). We found that diagnostic performance 393	
of CRP in our study population was limited by widely overlapping distributions between the three 394	
target infections, resulting in reduced utility for inpatient populations where these are the three 395	
commonest competing aetiologies. Similar low specificity for discriminating between all three 396	
infections was shown in a British case notes review study of HIV-infected adults admitted with 397	
respiratory infections (13). Conversely, our findings differed from a previous South African study that 398	
reported good discrimintaion of CRP (ROC AUC of 0.87) when comparing participants with 399	
pneumococcal community-acquired pneumonia and pulmonary tuberculosis (27). We suspect that the 400	
disparity may be attributable to differences in participant selection or to the small sample size in the 401	
other South African study. Another study found higher specificity (83%), sensitivity 69%, for 402	
combined CRP and IL-8 for discriminating bacerial pneumonia from PJP or mycobateriosis, in a 403	
cohort that included hospital-acquired infections and other mycobacterial infections beside 404	
tuberculosis (17).   405	
 406	
Guidelines for procalcitonin suggest that bacterial infection is present at a concentration of ≥0.25 µg/L 407	
(9).  Although this cut-off captured 82% of participants with CAP in our study, it also identified 84% 408	
of those with tuberculosis and 50% of those with PJP; therefore had limited value in distinguishing 409	
CAP from the other two infections. Procalcitonin distribution across the three infections in our cohort, 410	
with concentrations highest in CAP and lowest in PJP, were comparable to other studies in HIV-411	
infected individuals (27, 28). However, our findings did not mirror those of two other studies of 412	
inpatients with mixed HIV status, both of which found little overlap in procalcitonin concentrations 413	
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between any of the three target infections (27, 28). In Schleicher’s study, elevated procalcitonin (>0.1 414	
µg/L) was found in all participants with bacterial pneumonia and only 59% of the tuberculosis group, 415	
compared with 95% and 96% respectively in our study. Schleicher et al. and Lawn et al. noted a 416	
possible link between raised procalcitonin and lower CD4 count (27, 29). In our study we also found a 417	
moderate negative association between CD4 count and procalcitonin in patients with tuberculosis 418	
(Spearman’s rho -0.33, p-value=0.0001). Differing CD4 count medians (107 x 109 cells/L in 419	
Schleicher’s cohort compared with 77 x 109 cells/L in ours) may account for higher procalcitonin 420	
concentrations in our tuberculosis group.  421	
 422	
Mixed infection is a well-recognised limitation in diagnostic accuracy studies. Our study prevalence 423	
of 15.3% mixed infection compared to Nyamande’s reported 21% (28). In our study, elevated CRP 424	
was found in all 38 participants with mixed infection and elevated procalcitonin in 92%. Our 425	
participants with mixed infection had higher median concentrations of both CRP and procalcitonin 426	
than the participants with tuberculosis and PJP as single infections, but statistical significance was 427	
only found when comparing mixed infection to PJP as a single infection. Due to the difficulty in 428	
determining the extent of contribution of each infection to biomarker concentrations, the mixed 429	
infection group was excluded from diagnostic accuracy analyses.  430	
 431	
Our study has a number of limitations. First, reference standards for CAP and PJP did not include 432	
microbiological confirmation. Although blood and sputum cultures were carried out to detect bacterial 433	
infections, almost all were negative due to prior antibiotic use. However, even if cultures had been 434	
taken prior to antibiotics the sensitivity of sputum and blood cultures for CAP is low, and clinical case 435	
definitions of CAP are universally used in clinical research. Bronchoalveolar lavage, which is the 436	
optimal specimen for diagnosing PJP, was not available at either of our study hospitals. However, we 437	
adapted the CDC case definition for PJP, which had a sensitivity and specificity of 85% for diagnosis 438	
of PJP when compared with bronchoscopy (30). Furthermore, we found β-D-glucan exceeding 300 439	
pg/L in 13/16 of our participants fulfilling our PJP case definition. β-D-glucan had a sensitivity of 440	
92% and specificity of 78% for the diagnosis of PJP in HIV-infected patients in a systematic review 441	
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(31), and 91% sensitivity and 92% specificity for a β-D-glucan cut-off >300 (32). Conversely, 442	
elevated β-D-glucan in 11 participants with tuberculosis and one with CAP may represent 443	
unrecognized co-infection with PJP. Second, our sample size of participants with PJP was small. 444	
Third, CRP and procalcitonin concentrations may have been reduced by antibiotic treatment prior to 445	
providing a blood specimen at study enrolment. However, this is unlikely to have had a major effect as 446	
almost all of our participants received antibiotics within 24 hours of study enrolment. Study strengths 447	
include the use of a robust culture-based reference standard for tuberculosis and that our study 448	
participants were recruited from two urban district hospitals that represent a population typical of high 449	
HIV and TB burden settings. 450	
 451	
In conclusion, CRP and procalcitonin were both found to have limited value in distinguishing between 452	
the three common  infections due to widely overlapping distributions, particularly between 453	
tuberculosis and CAP. Future studies should include a larger sample of participants with PJP 454	
definitively diagnosed, as both biomarkers had best diagnostic accuracy for discriminating between 455	
PJP and the other two infections in our study. CRP and procalcitonin may have greater diagnostic 456	
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% CI 95% CI 99% CI 
Sensitivity 70% 80% 90% 70% 80% 90% 
TB       
n=133 61.66-77.07 72.07-85.66 84-94.2 69.41-87.17 69.41-87.17 81.56-95.06 
n=113 60.91-77.6 71.31-86.04 83.41-94.48 68.38-87.63 68.38-87.63 80.7-95.36 
CAP       
n=61  58.11-80.44 68.69-88.37 80.16-95.41 54.06-82.91 64.55-90.15 76.1-96.35 
n=52 55.73-80.09 68.10-89.2 79.4-95.82 51.38-82.73 63.58-91 74.9-96.3 
PJP       
n=16 44.4-85.84 57- 93.4 64-95.5 37.56-88.94 49.06- 95.12 55.5-97.52 
n=14 45.35-88.28 52.41-92.42 68.53-98.73 38.01-91.07 44.37-94.4 59-99.16 
Abbreviations: CI: confidence intervals, TB: tuberculosis, CAP: bacterial community-acquired pneumonia, PJP: Pneumocystis 
jirovecii pneumonia.  
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Table S2: Power calculation to detect C-reactive protein and procalcitonin concentration differences 638	
between target disease pairs  639	







effect size (%  
difference) 
Approximate power (%) with different error 
probabilities & sample sizes 
100% n (TB:133 
 CAP:61, PJP:16) 
85% n (TB:113, 
CAP:52, PJP:14) 
PCT ng/ml (95% CI)  
 




























































































































































































Abbreviations: CI: confidence intervals, TB: tuberculosis, CAP: bacterial community-acquired pneumonia, PJP: 





















Table S3: Baseline characteristics of 248 participants with a single target infection or mixed infection 659	


























n= 38 (15) 
P-value for pairwise comparison* 













TB vs. MI=0.66, CAP vs. MI=0.74,  




168 (68) 84 (63) 44(72) 11(69) 29(76) TB vs. MI=0.13, CAP vs. MI=0.65 




73 (29) 38(29) 18(30) 4(25) 13(34) TB vs. MI=0.50, CAP vs. MI=0.63 
PJP vs. MI= 0.75# 
 
Antiretroviral 
therapy n (%) 
93 (38) 43(32) 29(48) 4(25) 17(45) TB vs. MI=0.16, CAP vs. MI=0.79 
















TB vs. MI=0.9, CAP vs. MI=0.004 














TB vs. MI=0.005, CAP vs. 
MI=0.10 















TB vs. MI=0.05, CAP vs. MI=0.14 
PJP vs. MI=0.05 
 
Median CRP 













TB vs. MI: 0.52, CAP vs. MI: 0.25 














TB vs. MI: 0.96, CAP vs. MI: 0.26 
PJP vs. MI: 0.09 
PCT≥0.25 
µg/L n(%) 
200 (80.7) 112 (84.2) 50 (82.0) 8 (50.0) 30 (79.0) PTB vs. MI: 0.45, CAP vs. MI: 0.71 
PJP vs. MI: 0.03 
 















TB vs. MI=0.32, CAP vs. MI=0.66 















TB vs. MI=0.70, CAP vs. MI=0.73 















TB vs. MI=0.61, CAP vs. MI=0.80 
PJP vs. MI= 0.25 
 













TB vs. MI=0.20, CAP vs. MI=0.10 
PJP vs. MI=0.72 
Abbreviations: TB, tuberculosis; CAP, bacterial community-acquired pneumonia; PJP, Pneumocystis jirovecii pneumonia;  
MI: mixed infection; Hb: haemoglobin; WCC: white cell count; CRP, C-reactive protein; PCT, procalcitonin 
*Hypothesis tests- Wilcoxon-Mann-Whitney test for continuous data; Chi-square test for categorical data. #Fisher’s exact test where 
1 or more cells <5   
1 Danger signs based on WHO algorithm for diagnosis of TB in seriously ill patients. 
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Read the guidelines for tables.$
Read our policy on data availability.$
See our list of recommended repositories.$
Deposit data in the integrated repository of choice.!
Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for
reviewers to gain access to the data.
!
Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of
the PLOS submission form. Then provide the URL passcode in the Attach Files section.
!
In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is
accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these
numbers must be provided at submission.
Identifiers
As much as possible, please provide accession numbers or identifiers for all entities such as genes,
proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:
Identifiers should be provided in parentheses after the entity on first use.
Striking image
You can choose to upload a “Striking Image” that we may use to represent your article online in places like
the journal homepage or in search results.
The striking image must be derived from a figure or supporting information file from the submission, i.e., a
cropped portion of an image or the entire image. Striking images should ideally be high resolution, eye-
catching, single panel images, and should ideally avoid containing added details such as text, scale bars,
and arrows.
If no striking image is uploaded, we will designate a figure from the submission as the striking image.
Additional Information Requested at Submission
Funding Statement
This information should not be in your manuscript file; you will provide it via our submission system.
This information will be published with the final manuscript, if accepted, so please make sure that this is
accurate and as detailed as possible. You should not include this information in your manuscript file, but it
is important to gather it prior to submission, because your financial disclosure statement cannot be
changed after initial submission.
Your statement should include relevant grant numbers and the URL of any funder's web site. Please also
state whether any individuals employed or contracted by the funders (other than the named authors) played
any role in: study design, data collection and analysis, decision to publish, or preparation of the manuscript.
If so, please name the individual and describe their role.
Competing Interests
This information should not be in your manuscript file; you will provide it via our submission system.
All potential competing interests must be declared in full. If the submission is related to any patents, patent
applications, or products in development or for market, these details, including patent numbers and titles,
must be disclosed in full.
Manuscripts disputing published work
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review by the
disputed author during the peer review process. This procedure is aimed at ensuring a thorough,





Mouse Genome Database (MGD)!
Online Mendelian Inheritance in Man (OMIM)!
PubChem!
Striking images should not contain potentially identifying images of people.  Read our policy on identifying information. 
The PLOS licenses and copyright policy also applies to striking images.
#
Read our policy on disclosure of funding sources.$
Read our policy on competing interests.$
If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full
declaration of all competing interests. The Academic Editor will consider any such reviews in light of the
competing interest.
Authors submitting manuscripts disputing previous work should explain the relationship between the
manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this
review policy before the manuscript is considered further.
Related manuscripts
Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently
under consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or
elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to comment on
the overlap between related submissions.
We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not
consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be written as an
independent unit and should not rely on any work that has not already been accepted for publication. If
related manuscripts are submitted to PLOS ONE, the authors may be advised to combine them into a
single manuscript at the editor's discretion.
PLOS does support authors who wish to share their work early and receive feedback before formal peer
review. Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at
any PLOS journal.
Authors choosing bioRxiv may now concurrently submit directly to select PLOS journals through bioRxiv’s
direct transfer to journal service.
Guidelines for Specific Study Types
Human subjects research
All research involving human participants must have been approved by the authors’ Institutional Review Board (IRB) or by
equivalent ethics committee(s), and must have been conducted according to the principles expressed in the Declaration of
Helsinki. Authors should be able to submit, upon request, a statement from the IRB or ethics committee indicating approval of
the research. We reserve the right to reject work that we believe has not been conducted to a high ethical standard, even
when formal approval has been obtained. 
Subjects must have been properly instructed and have indicated that they consent to participate by signing the appropriate
informed consent paperwork. Authors may be asked to submit a blank, sample copy of a subject consent form. If consent
was verbal instead of written, or if consent could not be obtained, the authors must explain the reason in the manuscript, and
the use of verbal consent or the lack of consent must have been approved by the IRB or ethics committee. 
All efforts should be made to protect patient privacy and anonymity. Identifying information, including photos, should not be
included in the manuscript unless the information is crucial and the individual has provided written consent by completing the 
Consent Form for Publication in a PLOS Journal (PDF). Download additional translations of the form from the Downloads
and Translations page. More information about patient privacy, anonymity, and informed consent can be found in the
International Committee of Medical Journal Editors (ICMJE) Privacy and Confidentiality guidelines.
Manuscripts should conform to the following reporting guidelines:
Methods sections of papers on research using human subjects or samples must include ethics statements
that specify:
Read our policies on related manuscripts and preprint servers.$
Studies of diagnostic accuracy: STARD!
Observational studies: STROBE!
Microarray experiments: MIAME!
Other types of health-related research: Consult the EQUATOR web site for appropriate reporting guidelines!
The name of the approving institutional review board or equivalent committee(s). If approval was not obtained, the
authors must provide a detailed statement explaining why it was not needed
!
Whether informed consent was written or oral. If informed consent was oral, it must be stated in the manuscript:!
Why written consent could not be obtained!
That the Institutional Review Board (IRB) approved use of oral consent!
How oral consent was documented!
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender,
sexual orientation, or other socially constructed groupings, authors should:
In addition, outmoded terms and potentially stigmatizing labels should be changed to more current,
acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] European
descent” (as appropriate); “cancer victims” should be changed to “patients with cancer.”
For papers that include identifying, or potentially identifying, information, authors must download
the Consent Form for Publication in a PLOS Journal, which the individual, parent, or guardian must sign
once they have read the paper and been informed about the terms of PLOS open-access license. The
signed consent form should not be submitted with the manuscript, but authors should securely file it in the
individual's case notes and the methods section of the manuscript should explicitly state that consent
authorization for publication is on file, using wording like:
The individual in this manuscript has given written informed consent (as outlined in PLOS consent
form) to publish these case details.
For more information about PLOS ONE policies regarding human subjects research, see the Publication
Criteria and Editorial Policies.
Clinical trials
Clinical trials are subject to all policies regarding human research. PLOS ONE follows the World Health
Organization's (WHO) definition of a clinical trial:
A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more
health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to
drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments,
process-of-care changes, preventive care, etc.
All clinical trials must be registered in one of the publicly-accessible registries approved by
the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must provide the trial
registration number. Prior disclosure of results on a clinical trial registry site will not affect consideration for
publication. We reserve the right to inform authors' institutions or ethics committees, and to reject the
manuscript, if we become aware of unregistered trials.
PLOS ONE supports prospective trial registration (i.e. before participant recruitment has begun) as
recommended by the ICMJE's clinical trial registration policy. Where trials were not publicly registered
before participant recruitment began, authors must:
Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT for
randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as
appropriate. The intervention should be described according to the requirements of the TIDieR checklist
and guide. Submissions must also include the study protocol as supporting information, which will be
published with the manuscript if accepted.
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting
guidelines appropriate to their trial design, available on the CONSORT Statement web site. Before the
paper can enter peer review, authors must:
Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss
informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form.
The methods section must include the name of the registry, the registry number, and the URL of your trial in
the registry database for each location in which the trial is registered.
Animal research
Explicitly describe their methods of categorizing human populations!
Define categories in as much detail as the study protocol allows!
Justify their choices of definitions and categories, including for example whether any rules of human categorization were
required by their funding agency
!
Explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition,
environmental exposures, or similar factors in their analysis
!
Register all related clinical trials and confirm they have done so in the Methods section!
Explain in the Methods the reason for failing to register before participant recruitment!
Provide the registry name and number in the methods section of the manuscript!
Provide a copy of the trial protocol as approved by the ethics committee and a completed CONSORT checklist as supporting
information (which will be published alongside the paper, if accepted). This should be named S1 CONSORT Checklist.
!
Include the CONSORT flow diagram as the manuscript's “Fig 1”!
All research involving vertebrates or cephalopods must have approval from the authors' Institutional Animal Care and Use
Committee (IACUC) or equivalent ethics committee(s), and must have been conducted according to applicable national and
international guidelines. Approval must be received prior to beginning research.
Manuscripts reporting animal research must state in the Methods section:
Example ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize suffering.
Authors should always state the organism(s) studied in the Abstract. Where the study may be confused as
pertaining to clinical research, authors should also state the animal model in the title.
To maximize reproducibility and potential for re-use of data, we encourage authors to follow the Animal
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all submissions describing laboratory-
based animal research and to upload a completed ARRIVE Guidelines Checklist to be published as
supporting information.
Non-human primates
Manuscripts describing research involving non-human primates must report details of husbandry and
animal welfare in accordance with the recommendations of the Weatherall report, The use of non-human
primates in research (PDF), including:
Random source animals
Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the USA), shelter,
or stray animals will be subject to additional scrutiny and may be rejected if sufficient ethical and scientific
justification for the study design is lacking.
Unacceptable euthanasia methods and anesthetic agents
Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the American
Veterinary Medical Association or use of an anesthesia method(s) that is widely prohibited (e.g., chloral
hydrate, ether, chloroform) must include at the time of initial submission, scientific justification for use in the
specific study design, as well as confirmation of approval for specific use from their animal research ethics
committee. These manuscripts may be subject to additional ethics considerations prior to publication.
Humane endpoints
Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) is a likely
outcome or a planned experimental endpoint, must comprehensively report details of study design,
rationale for the approach, and methodology, including consideration of humane endpoints. This applies to
research that involves, for instance, assessment of survival, toxicity, longevity, terminal disease, or high
rates of incidental mortality.
Definition of a humane endpoint 
A humane endpoint is a predefined experimental endpoint at which animals are euthanized when they display early markers
associated with death or poor prognosis of quality of life, or specific signs of severe suffering or distress. Humane endpoints
are used as an alternative to allowing such conditions to continue or progress to death following the experimental intervention
(“death as an endpoint”), or only euthanizing animals at the end of an experiment. Before a study begins, researchers define
the practical observations or measurements that will be used during the study to recognize a humane endpoint, based on
anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines for more information. Additional
discussion of humane endpoints can be found in this article:  Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson
(2012) How “Humane” Is Your Endpoint? — Refining the Science-Driven Approach for Termination of Animal Studies of
Chronic Infection. PLoS Pathog 8(1): e1002399 doi.org/10.1371/journal.ppat.1002399.
Full details of humane endpoints use must be reported for a study to be reproducible and for the results to
be accurately interpreted.
The full name of the relevant ethics committee that approved the work, and the associated permit number(s).!
Where ethical approval is not required, the manuscript should include a clear statement of this and the reason why. Provide
any relevant regulations under which the study is exempt from the requirement for approval.
!
Relevant details of steps taken to ameliorate animal suffering.!
Information about housing, feeding, and environmental enrichment.!
Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if appropriate.!
For studies in which death of an animal is an outcome or a planned experimental endpoint, authors should
include the following information in the Methods section of the manuscript:
If humane endpoints were not used, the manuscript should report:
Observational and field studies
Methods sections for submissions reporting on any type of field study must include ethics statements that
specify:
Paleontology and archaeology research
Manuscripts reporting paleontology and archaeology research must include descriptions of methods and
specimens in sufficient detail to allow the work to be reproduced. Data sets supporting statistical and
phylogenetic analyses should be provided, preferably in a format that allows easy re-use. Read the policy.
Specimen numbers and complete repository information, including museum name and geographic location,
are required for publication. Locality information should be provided in the manuscript as legally allowable,
or a statement should be included giving details of the availability of such information to qualified
researchers.
If permits were required for any aspect of the work, details should be given of all permits that were
obtained, including the full name of the issuing authority. This should be accompanied by the following
statement:
All necessary permits were obtained for the described study, which complied with all relevant regulations.
If no permits were required, please include the following statement:
No permits were required for the described study, which complied with all relevant regulations.
Manuscripts describing paleontology and archaeology research are subject to the following policies:
Systematic reviews and meta-analyses
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly formulated
question that uses explicit, systematic methods to identify, select, and critically appraise relevant research,
and to collect and analyze data from the studies that are included in the review. These reviews differ
substantially from narrative-based reviews or synthesis articles. Statistical methods (meta-analysis) may or
may not be used to analyze and summarize the results of the included studies.
Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text.
Blank templates are available here:
The specific criteria (i.e. humane endpoints) used to determine when animals should be euthanized.!
The duration of the experiment.!
The numbers of animals used, euthanized, and found dead (if any); the cause of death for all animals.!
How frequently animal health and behavior were monitored.!
All animal welfare considerations taken, including efforts to minimize suffering and distress, use of analgesics or
anaesthetics, or special housing conditions.
!
A scientific justification for the study design, including the reasons why humane endpoints could not be used, and discussion
of alternatives that were considered.
!
Whether the institutional animal ethics committee specifically reviewed and approved the anticipated mortality in the study
design.
!
Permits and approvals obtained for the work, including the full name of the authority that approved the study; if none were
required, authors should explain why
!
Whether the land accessed is privately owned or protected!
Whether any protected species were sampled!
Full details of animal husbandry, experimentation, and care/welfare, where relevant!
Sharing of data and materials. Any specimen that is erected as a new species, described, or figured must be deposited
in an accessible, permanent repository (i.e., public museum or similar institution). If study conclusions depend on
specimens that do not fit these criteria, the article will be rejected under PLOS ONE's data availability criterion.
!
Ethics. PLOS ONE will not publish research on specimens that were obtained without necessary permission or were
illegally exported.
!
Checklist: PDF or Word document!
Authors must also state in their “Methods” section whether a protocol exists for their systematic review, and
if so, provide a copy of the protocol as supporting information and provide the registry number in the
abstract.
If your article is a systematic review or a meta-analysis you should:
Meta-analysis of genetic association studies
Manuscripts reporting a meta-analysis of genetic association studies must report results of value to the field
and should be reported according to the guidelines presented in Systematic Reviews of Genetic
Association Studies by Sagoo et al.
On submission, authors will be asked to justify the rationale for the meta-analysis and how it contributes to
the base of scientific knowledge in the light of previously published results. Authors will also be asked to
complete a checklist (DOCX) outlining information about the justification for the study and the methodology
employed. Meta-analyses that replicate published studies will be rejected if the authors do not provide
adequate justification.
Personal data from third-party sources
For all studies using personal data from internet-based and other third-party sources (e.g., social media,
blogs, other internet sources, mobile phone companies), data must be collected and used according to
company/website Terms and Conditions, with appropriate permissions. All data sources must be
acknowledged clearly in the Materials and Methods section.
In the Ethics Statement, authors should declare any potential risks to individuals or individual privacy, or
affirm that in their assessment, the study posed no such risks. In addition, the following Ethics and Data
Protection requirements must be met.
For interventional studies, which impact participants’ experiences or data, the study design must have
been prospectively approved by an Ethics Committee, and informed consent is required. The Ethics
Committee may waive the requirement for approval and/or consent.
For observational studies in which personal experiences and accounts are not manipulated, consultation
with an Ethics or Data Protection Committee is recommended. Additional requirements apply in the
following circumstances:
Note that Terms of Use contracts do not qualify as informed consent, even if they address the use of personal data for
research. 
Cell lines
Authors reporting research using cell lines should state when and where they obtained the cells, giving the
date and the name of the researcher, cell line repository, or commercial source (company) who provided
the cells, as appropriate.
Authors must also include the following information for each cell line:
For de novo (new) cell lines, including those given to the researchers as a gift, authors must follow our
policies for human subjects research or animal research, as appropriate. The ethics statement must
include:
Flow diagram: PDF or Word document!
State this in your cover letter!
Select “Research Article” as your article type when submitting!
Include the PRISMA flow diagram as Fig 1 (required where applicable)!
Include the PRISMA checklist as supporting information!
Read our policy on data availability.    $
If information used could threaten personal privacy or damage the reputation of individuals whose data are used, an Ethics
Committee should be consulted and informed consent obtained or specifically addressed.
!
If authors accessed any personal identifying information, an Ethics or Data Protection Committee should oversee data
anonymization. If data were anonymized and/or aggregated before access and analysis, informed consent is generally not
required.
!
See our reporting guidelines for human subjects research.$
For established cell lines, the Methods section should include:
Authors should check established cell lines using the ICLAC Database of Cross-contaminated or
Misidentified Cell Lines to confirm they are not misidentified or contaminated. Cell line authentication is
recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats (STR) analysis – and may
be required during peer review or after publication.
Blots and gels
Manuscripts reporting results from blots (including Western blots) and electrophoretic gels should follow
these guidelines:
Antibodies
Manuscripts reporting experiments using antibodies should include the following information:
The manuscript should also report the following experimental details:
We encourage authors to consider adding information on new validations to a publicly available database such as
Antibodypedia or CiteAb.
Small and macromolecule crystal data
Manuscripts reporting new and unpublished three-dimensional structures must include sufficient supporting
data and detailed descriptions of the methodologies used to allow the reproduction and validation of the
structures. All novel structures must have been deposited in a community endorsed database prior to
submission (please see our list of recommended repositories).
Small molecule single crystal data
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic
molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the Inorganic
Crystal Structure Database (ICSD), or similar community databases providing a recognized validation
functionality. Authors are also required to include the relevant structure reference numbers within the main
text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif format) as
Supplementary Information, along with the checkCIF validation reports that can be obtained via the
International Union of Crystallography (IUCr).
Macromolecular structures
Authors reporting novel macromolecular structures must have deposited their data prior to submission with
the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank (BMRB), the
Electron Microscopy Data Bank (EMDB), or other community databases providing a recognized validation
Details of institutional review board or ethics committee approval; AND!
For human cells, confirmation of written informed consent from the donor, guardian, or next of kin!
A reference to the published article that first described the cell line; AND/OR!
The cell line repository or company the cell line was obtained from, the catalogue number, and whether the cell line was
obtained directly from the repository/company or from another laboratory
!
In accordance with our policy on image manipulation, the image should not be adjusted in any way that could affect the
scientific information displayed, e.g. by modifying the background or contrast. 
!
All blots and gels that support results reported in the manuscript should be provided.!
Original uncropped and unadjusted blots and gels, including molecular size markers, should be provided in either the figures
or the supplementary files.
!
Lanes should not be overcropped around the bands; the image should show most or all of the blot or gel. Any non-specific
bands should be shown and an explanation of their nature should be given.
!
The image should include all relevant controls, and controls should be run on the same blot or gel as the samples.!
A figure panel should not include composite images of bands originating from different blots or gels. If the figure shows non-
adjacent bands from the same blot or gel, this should be clearly denoted by vertical black lines and the figure legend should
provide details of how the figure was made.
!
The name of each antibody, a description of whether it is monoclonal or polyclonal, and the host species.!
The commercial supplier or source laboratory.!
The catalogue or clone number and, if known, the batch number.!
The antigen(s) used to raise the antibody.!
For established antibodies, a stable public identifier from the Antibody Registry.!
The final antibody concentration or dilution.!
A reference to the validation study if the antibody was previously validated. If not, provide details of how the authors validated
the antibody for the applications and species used. 
!
functionality. Authors must include the structure reference numbers within the main text and submit as
Supplementary Information the official validation reports from these databases.
Methods, software, databases, and tools
PLOS ONE will consider submissions that present new methods, software, or databases as the primary
focus of the manuscript if they meet the following criteria:
Utility 
The tool must be of use to the community and must present a proven advantage over existing alternatives, where applicable.
Recapitulation of existing methods, software, or databases is not useful and will not be considered for publication. Combining
data and/or functionalities from other sources may be acceptable, but simpler instances (i.e. presenting a subset of an
already existing database) may not be considered. For software, databases, and online tools, the long-term utility should also
be discussed, as relevant. This discussion may include maintenance, the potential for future growth, and the stability of the
hosting, as applicable. 
Validation 
Submissions presenting methods, software, databases, or tools must demonstrate that the new tool achieves its intended
purpose. If similar options already exist, the submitted manuscript must demonstrate that the new tool is an improvement
over existing options in some way. This requirement may be met by including a proof-of-principle experiment or analysis; if
this is not possible, a discussion of the possible applications and some preliminary analysis may be sufficient. 
Availability 
If the manuscript’s primary purpose is the description of new software or a new software package, this software must be
open source, deposited in an appropriate archive, and conform to the Open Source Definition. If the manuscript mainly
describes a databse, this database must be open-access and hosted somewhere publicly accessible, and any software used
to generate a database should also be open source. If relevant, databases should be open for appropriate deposition of
additional data. Dependency on commercial software such as Mathematica and MATLAB does not preclude a paper from
consideration, although complete open source solutions are preferred. In these cases, authors should provide a direct link to
the deposited software or the database hosting site from within the paper.
Software submissions
Manuscripts whose primary purpose is the description of new software must provide full details of the
algorithms designed. Describe any dependencies on commercial products or operating system. Include
details of the supplied test data and explain how to install and run the software. A brief description of
enhancements made in the major releases of the software may also be given. Authors should provide a
direct link to the deposited software from within the paper.
Database submissions
For descriptions of databases, provide details about how the data were curated, as well as plans for long-
term database maintenance, growth, and stability. Authors should provide a direct link to the database
hosting site from within the paper.
New taxon names
Zoological names
When publishing papers that describe a new zoological taxon name, PLOS aims to comply with the
requirements of the International Commission on Zoological Nomenclature (ICZN). Effective 1 January
2012, the ICZN considers an online-only publication to be legitimate if it meets the criteria of archiving and
is registered in ZooBank, the ICZN's official registry.
For proper registration of a new zoological taxon, we require two specific statements to be included in your
manuscript.
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier
(LSID), should be listed under the new species name, for example:
Anochetus boltoni Fisher sp. nov. urn:lsid:zoobank.org:act:B6C072CF-1CA6-40C7-8396-534E91EF7FBB
You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as possible to avoid
delay of publication upon acceptance of your manuscript. It is your responsibility to provide us with this
information so we can include it in the final published paper.
Please also insert the following text into the Methods section, in a sub-section to be called “Nomenclatural
Acts”:
The electronic edition of this article conforms to the requirements of the amended International Code of Zoological
Read the PLOS policy on sharing materials and software.$
Nomenclature, and hence the new names contained herein are available under that Code from the electronic edition of this
article. This published work and the nomenclatural acts it contains have been registered in ZooBank, the online registration
system for the ICZN. The ZooBank LSIDs (Life Science Identifiers) can be resolved and the associated information viewed
through any standard web browser by appending the LSID to the prefix “http://zoobank.org/”. The LSID for this publication is:
urn:lsid:zoobank.org:pub: XXXXXXX. The electronic edition of this work was published in a journal with an ISSN, and has
been archived and is available from the following digital repositories: PubMed Central, LOCKSS [author to insert any
additional repositories].
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co-
authors, has its own repository, we recommend that you also deposit the published online article there and
include the name in your article.
Botanical names
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements
of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for
publication in an online-only journal have been agreed such that any scientific botanical name published by
us is considered effectively published under the rules of the Code. Please note that these guidelines differ
from those for zoological nomenclature, and apply only to seed plants, ferns, and lycophytes.
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This
does not affect the requirements for scientific names, which are still to be Latin.
Also effective January 2012, the electronic PDF represents a published work according to the ICN for
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article
are effectively published under that Code from the electronic edition alone, so there is no longer any need
to provide printed copies.
Additional information describing recent changes to the Code can be found here.
For proper registration of the new taxon, we require two specific statements to be included in your
manuscript.
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier
(LSID), should be listed under the new species name, for example:
Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: Colombia. Putumayo: vertiente oriental
de la Cordillera, entre Sachamates y San Francisco de Sibundoy, 1600-1750 m, 30 Dec 1940, J. Cuatrecasas 11471
(holotype, COL; isotypes, F [F-1335119], US [US-1799731]).
Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted for publication,
and this information will then be added to the manuscript during the production phase
In the Methods section, include a sub-section called “Nomenclature” using the following wording:
The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a
published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names
contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition
alone, so there is no longer any need to provide printed copies. 
In addition, new names contained in this work have been submitted to IPNI, from where they will be made available to the
Global Names Index. The IPNI LSIDs can be resolved and the associated information viewed through any standard web
browser by appending the LSID contained in this publication to the prefix http://ipni.org/. The online version of this work is
archived and available from the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES WHERE
ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed Central, LOCKSS etc)].
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co-
authors, has its own repository, we recommend that you also deposit the published online article there and
include the name in your article.
Fungal names
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements
of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for
publication in an online-only journal have been agreed such that any scientific botanical name published by
us is considered effectively published under the rules of the Code. Please note that these guidelines differ
from those for zoological nomenclature.
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This
does not affect the requirements for scientific names, which are still to be Latin.
Also effective January 2012, the electronic PDF represents a published work according to the ICN for
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article
are effectively published under that Code from the electronic edition alone, so there is no longer any need
to provide printed copies.
Additional information describing recent changes to the Code can be found here.
For proper registration of the new taxon, we require two specific statements to be included in your
manuscript.
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier
(LSID), should be listed under the new species name, for example:
Hymenogaster huthii. Stielow et al. 2010, sp. nov. [urn:lsid:indexfungorum.org:names:518624]
You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). Please do this as
early as possible to avoid delay of publication upon acceptance of your manuscript. It is your responsibility
to provide us with this information so we can include it in the final published paper. Effective January 2013,
all papers describing new fungal species must reference the identifier issued by a recognized repository in
the protologue in order to be considered effectively published.
In the Methods section, include a sub-section called “Nomenclature” using the following wording (this
example is for taxon names submitted to MycoBank; please substitute appropriately if you have submitted
to Index Fungorum):
The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a
published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names
contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition
alone, so there is no longer any need to provide printed copies. 
In addition, new names contained in this work have been submitted to MycoBank from where they will be made available to
the Global Names Index. The unique MycoBank number can be resolved and the associated information viewed through any
standard web browser by appending the MycoBank number contained in this publication to the prefix
http://www.mycobank.org/MB/. The online version of this work is archived and available from the following digital repositories:
[INSERT NAMES OF DIGITAL REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed
Central, LOCKSS etc)].
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your co-
authors, has its own repository, we recommend that you also deposit the published online article there and
include the name in your article.
Qualitative research
Qualitative research studies use non-quantitative methods to address a defined research question that may
not be accessible by quantitative methods, such as people's interpretations, experiences, and perspectives.
The analysis methods are explicit, systematic, and reproducible, but the results do not involve numerical
values or use statistics. Examples of qualitative data sources include, but are not limited to, interviews, text
documents, audio/video recordings, and free-form answers to questionnaires and surveys.
Qualitative research studies should be reported in accordance to the Consolidated criteria for reporting
qualitative research (COREQ) checklist. Further reporting guidelines can be found in the Equator
Network's Guidelines for reporting qualitative research.
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